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Staphylococcus aureus Panton-Valentine leukocidin (PVL) alters human 
neutrophil viability and function 
Chairperson:  Jesse Hay, Ph.D. 
  Community-associated methicillin-resistant S. aureus (CA-MRSA) 
infections are the leading cause of community bacterial infections in the United 
States. Genes encoding Panton-Valentine leukocidin (PVL) are present in most 
Staphylococcus aureus strains that cause CA-MRSA infections. Despite an 
association of PVL with the most abundant CA-MRSA strains, its role in 
pathogenesis—if any—remains unknown. PVL is a pore-forming toxin with 
specificity for myeloid cells, including polymorphonuclear leukocytes (PMNs or 
neutrophils). It is widely assumed that PVL-mediated pore formation in the 
plasma membrane of PMNs leads ultimately to cytolysis. However, this 
hypothesis has not been tested and previous studies indicate that levels of PVL 
in vivo are likely insufficient to cause host cell lysis. On the other hand, sublytic 
concentrations of PVL prime neutrophils for enhanced production of reactive 
oxygen species (ROS), and cause secretion of proinflammatory molecules and 
granule exocytosis. The molecular basis of PVL-mediated priming is unknown. 
To better understand the role played by PVL during S. aureus infection, we used 
human PMNs to investigate the correlation between PVL-mediated pore 
formation and cytolysis, and the molecular basis of PVL-mediated priming. Using 
S. aureus culture conditions that favor high production of PVL, there was on 
average more neutrophil plasma membrane permeability and cell lysis caused by 
supernatants derived from wild-type (PVL-positive) CA-MRSA strains compared 
to those from isogenic lukS/F-PV negative (PVL-negative) strains. Unexpectedly, 
there was not always a correlation between pore formation and cell lysis caused 
by S. aureus culture supernatants, and these findings were confirmed using 
purified PVL. Consistent with published studies, sublytic concentrations of PVL 
primed neutrophils for enhanced release of superoxide, caused upregulation of 
CD11b, and accelerated apoptosis. Microarray analysis revealed changes in the 
PMN transcriptome following exposure to PVL, including upregulation of 
molecules involved in the proinflammatory response. Consistent with microarray 
data, multiple proinflammatory molecules were released from neutrophils after 
stimulation with PVL. We propose that the primary function of PVL is distinct from 
leukocyte lysis—namely, that it elicits a proinflammatory response that can 
enhance the host innate immune response to S. aureus infection.   
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Methicillin-resistant Staphylococcus aureus 
 
1.1.1 Staphylococcus aureus (S. aureus) and the emergence of methicillin-
resistance  
S. aureus is a Gram-positive bacterium that has a long history of causing 
a wide range of infections in the human host. The pathogen is among the leading 
causes of mortality by single infectious agents in the U.S. (1,2). S. aureus is also 
notorious for its ability to acquire resistance to antibiotics. For example, penicillin 
was introduced to treat human infections in the early 1940s and penicillin-
resistant strains (PRSA) emerged soon thereafter (by 1942) (3). The molecule 
responsible for penicillin-resistance was identified as penicillinase (beta-
lactamase), a plasmid-encoded enzyme that binds and hydrolyzes the beta-
lactam ring of penicillin, rendering the antibiotic ineffective for treatment of 
infection (4). Strains expressing penicillinase were frequently isolated from 
patients without prior penicillin treatment, indicating in-hospital transmission of 
resistant strains (5). As such, the prevalence of penicillin-resistance in 
Staphylococcus increased dramatically within nosocomial settings (6). A 
penicillin-resistant Staphylococcus aureus strain known as phage-type 80/81 
became prominent in Australia in hospitals and the community in the 1950s and 
1960s (7). Phage-type 80/81 strains ultimately became epidemic worldwide (8,9). 
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By the mid-1950s, phage-type 80 strains were the cause of 42 percent of all 
outbreaks (9).  
Methicillin was introduced in 1959 to treat S. aureus infections, largely 
because of the increased incidence of PRSA (10). Emergence of methicillin-
resistant S. aureus (MRSA) occurred rapidly and initial reports of methicillin-
resistant strains were published in 1961; however, outbreaks remained sporadic 
until the late 1960s. Industrialized countries reported increasing numbers of 
nosocomial MRSA infections in the later part of the decade (11-14) and there 
were warnings that MRSA would become problematic for hospitals worldwide 
(15-22). In 1975, 2.4 percent of S. aureus strains isolated from US hospitals were 
methicillin-resistant. By comparison, 29 percent of S. aureus isolates in 1991 
were MRSA (23).  
Methicillin-resistance is conferred by the mecA gene, which is encoded on 
a mobile genetic element known as the Staphylococcal chromosome cassette 
mec (SCCmec) (24). The mecA gene encodes a low-affinity penicillin-binding 
protein, PBP2a, that enables bacterial cell wall synthesis to continue in the 
presence of beta-lactam antibiotics (25). Currently, eight different SCCmec types 
have been identified (I-VIII). SCCmec types I-III, and VIII encode for resistance to 
multiple antibiotics, including methicillin-resistance (mecA), while types IV-VII 
encode methicillin-resistance only (26).  
  In contrast to the PRSA pandemic, MRSA outbreaks remained largely 
within the hospital setting for 30 years and MRSA is now endemic in hospitals 
throughout the developed world (27-29). Immune compromised patients or 
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individuals with a predisposing risk factor, such as surgery, are particularly 
susceptible to infection. In addition, transmission and spread of MRSA is 
promoted in the healthcare setting by hospital staff colonized with MRSA (29,30). 
Nasal carriage of MRSA (endogenous reservoirs) was reported as a risk factor 
for bacteremia and infection of surgical sites (31-34). MRSA infections in which 
disease onset originated from a healthcare institution is known as hospital-
associated MRSA (HA-MRSA). The use of antibiotics in healthcare settings has  
 
 
 
 
 
 
 
 
selected for HA-MRSA strains that are resistant to several antimicrobial agents.  
As such, HA-MRSA strains typically harbor the larger SCCmec types that encode 
resistance to multiple antibiotics (26). The rapid emergence of strains that are 
resistant to multiple antibiotics underscores the need to develop new 
therapeutics for treatment of MRSA infections (11,30,35) (Fig. 1). 
 
1.1.2 Community-associated methicillin-resistant S.  aureus (CA-MRSA)  
Figure 1. Timeline depicting the emergence of penicillin and methicillin-
resistant S. aureus strains from 1940 to 2010. Green boxes represent 
introduction of an antibiotic and emergence of antibiotic-resistant strains. 
Blue boxes represent dissemination of resistant strains. 
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The epidemiology of MRSA infections changed in the early 1990s. 
Although MRSA continued to be a prominent cause of hospital-associated 
infections, there were reports of MRSA outbreaks involving individuals outside of 
the healthcare setting. In 1993, Udo et al. reported CA-MRSA infections in 
individuals from the remote Kimberley region of Western Australia (Fig. 1) (36). 
The Centers for Disease Control and Prevention (CDC) and Herold et al. 
subsequently reported severe infections in pediatric patients in the Midwestern 
U.S. and these individuals also had no prior hospital exposure (37,38). These 
articles were among the first to report bona fide CA-MRSA infections. The 
prevalence of pediatric cases treated for MRSA contracted in communities rose 
from 10/100,000 admissions in 1988-1990 to 259/100,000 admissions in 1993 to 
1995 (37). 
CA-MRSA infections became widespread after 2003 (39) and ultimately 
became epidemic in the U.S. (1,29). For example, MRSA was the causative 
agent of 59 percent of all US community-associated bacterial infections in 2004 
(29). These community-associated MRSA (CA-MRSA) infections often occurred 
in healthy, young populations such as athletic teams, preschool children, and 
military personnel (2,40,41). Skin and soft tissue infections compromise about 90 
percent of all CA-MRSA infections (41). Severe CA-MRSA disease, such as 
osteomyelitis, sepsis, or necrotizing pneumonia, is infrequent but these 
syndromes can cause death (38,42,43-45). The ability of CA-MRSA strains to 
cause infection in otherwise healthy individuals suggests that these strains have 
increased virulence compared to strains that typically cause hospital infections. 
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CA-MRSA outbreaks typically occur in close-quarter environments. Direct 
contact between hosts is considered to be the primary mode of transmission 
(46). Contaminated fomites, such as towels and whirlpools, shared by multiple 
individuals may also contribute to spread of CA-MRSA (42,47). The CDC has 
developed the “Five C’s” or a list of five factors that are associated with risk of 
infection: 1) crowded environments; 2) frequent skin-to-skin contact with an 
infected or colonized person; 3) compromised skin (skin injuries); 4) 
contaminated items or surfaces; 5) lack of cleanliness or personal hygiene 
(http://www.cdc.gov/niosh/topics/mrsa/). In addition, the CDC provides specific 
guidelines to prevent further spread of CA-MRSA infections as follows: 1) keep 
the infected area covered with a clean, dry bandage; 2) wash hands with soap 
and water or use an alcohol-based hand gel, particularly after touching the 
infected area 3) maintain good personal hygiene 4) avoid sharing items that were 
exposed to the affected area with other individuals; 5) consistently launder 
clothing that has come in contact with the infected area; 6) limit activities 
involving skin-to-skin contact if infected area cannot be covered with a clean, dry 
bandage; 7) clean shared surfaces or equipment with detergent/disinfectant that 
specifies S. aureus on the product label (http://www.cdc.gov/ncidod/dhqp/pdf/ar/ 
CAMRSA _ExpMtgStrategies.pdf). Application of the topical antibiotic mupirocin 
was recommended by Raz et al. to control recurrent CA-MRSA outbreaks (48). 
Notwithstanding, a study completed within the military population suggested such 
treatment does not decrease CA-MRSA colonization rates (49).  
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One method to categorize or type strains is based on pulsed-field gel 
electrophoresis (PFGE).  PFGE banding patterns of S. aureus strains with the 
same or similar patterns belong to the same PFGE type (11,45). Comparison of 
PFGE banding patterns from different isolates provides information about the 
relatedness of the isolates and is appropriate for understanding the molecular 
epidemiology of outbreaks. Isolates from community-associated infections are 
genetically distinct from those that cause hospital-associated infections, 
suggesting there has been de novo emergence of the most prominent CA-MRSA 
strains rather than emergence from existing prominent HA-MRSA strains (50). 
The predominant HA-MRSA strains in the U.S. are PFGE types USA100, 
USA200, USA500, USA600, and USA800 (52). To date, the CA-MRSA epidemic 
in the U.S. consists of two predominant PFGE types, USA400 and USA300 
(29,30,38,40-42). In addition to PFGE, multi-locus sequence typing (MLST or ST) 
can be used to determine the molecular epidemiology of MRSA infections. The 
ST of each strain is determined by single nucleotide polymorphisms (SNPs) 
present in seven housekeeping genes. Strains that have identical sequences at 
all seven loci are assigned to the same ST (11,51). 
USA400 outbreaks occurred in the late 1990s; however, the occurrence of 
USA400 infections has diminished in the US and USA300 has become the main 
cause of CA-MRSA infections (Fig. 1) (29,52). The molecular basis for the 
success of USA400 and USA300 as human pathogens remains unclear. Whole 
genome sequencing and analysis of MW2, the prototype USA400 strain (53), and 
FPR3757, a USA300 strain representative of the epidemic USA300 clone (54), 
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revealed novel genetic elements that could enhance dissemination and/or 
pathogenicity. One of the notable findings was the presence of a prophage 
(phiSA2mw in MW2 and phiSA2usa in FPR3757) containing genes encoding 
Panton-Valentine leukocidin (PVL). The PVL genes (lukS-PV and lukF-PV) are 
present in 2-5 percent of S. aureus isolates worldwide (2,55,56). Despite the 
overall low percentage of S. aureus strains that harbor genes encoding PVL, the 
most prominent causes of CA-MRSA infections in the U.S. and Canada are PVL-
positive strains. PVL is an exotoxin that forms pores in the plasma membrane of 
neutrophils, monocytes, and macrophages, host cells critical for host defense 
against S. aureus. Therefore, the emergence and success of CA-MRSA as a 
human pathogen was initially attributed to the presence of PVL in these strains 
(56-59). 
 
1.1.3 S. aureus evasion of human innate immunity  
In general, the ability of bacteria to cause disease is linked to evasion of 
the innate immune response. Polymorphonuclear leukocytes (PMNs or 
neutrophils) are the most abundant cells of the innate immune system and are 
essential for host defense against invading microbes (60). The importance of 
these leukocytes in the control and clearance of S. aureus infections is 
exemplified by patients with primary neutrophil defects. Deficiencies in 
phagocytic function, especially in neutrophils, result in recurrent and possibly 
fatal bacterial infections in these individuals (61). S. aureus is one of the leading 
causes of infection in patients with primary neutrophil defects. 
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Release of cytokines and chemokines from the tissue or cells surrounding 
the site of infection elicits an inflammatory response that includes rapid 
recruitment of PMNs in vivo. Molecules secreted by bacteria or components of 
the bacterial cell wall may also induce neutrophil chemotaxis and recruitment 
(62,63). Exposure of neutrophils to cytokines, chemokines, or bacterial 
components such as lipopolysacharride (LPS) in vitro primes these phagocytes 
for enhanced production of reactive oxygen species (ROS) and granule 
exocytosis following a secondary stimulus (Fig. 2) (64). N-formyl-methionyl- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Neutrophil 
degranulation and release of 
ROS after phagocytosis. A) 
Phagocytosis is facilitated by 
host serum proteins (antibodies 
and/or complement) that bind to 
the microbial surface. Following 
phagocytosis, granules fuse 
with the phagosomal 
membrane and release 
antimicrobial proteins into the 
phagosome. Superoxide (O2-) 
is also released into the 
phagosome following 
phagocytosis of microbes. B) A 
transmission electron 
micrograph of a human 
neutrophil that has 
phagocytosed S. aureus 
(microbe). Reprinted with 
permission from Wiley 
Interdiscip. Rev. Syst. Biol. 
Med. (64). 
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leucyl-phenylalanine (fMLP), a representative of bacterial N-formyl peptides, is 
often utilized as the secondary stimulus in in vitro assays. PMN priming also 
upregulates expression of surface receptors such as CR3 (CD11b/CD18), 
molecules involved in cell adhesion, phagocytosis, and activation (65-68).  
At the site of infection, PMNs rapidly engulf bacteria (a process known as 
phagocytosis), which are then sequestered within forming phagosomes (Fig. 2).  
The process of phagocytosis is facilitated by host serum proteins (such as  
antibody and complement) that opsonize microorganisms. Cytoplasmic granules  
fuse with the phagosomal membrane and antimicrobial proteins such as alpha-
defensins are enriched in the phagosome. Concurrently, phagocytosis activates 
a membrane bound NADPH oxidase to produce superoxide, which is then 
converted to numerous secondary ROS within the phagosome (69-71). These 
secondarily-derived ROS include hypochlorous acid, a primary constituent of 
household bleach (60,70) Exposure of the pathogen to such harsh, intracellular 
conditions enables PMNs to kill the ingested microbes while preventing non-
specific damage to host tissues.  
Neutrophils are widely known to be associated with inflammatory diseases 
such as rheumatoid arthritis, and can cause significant destruction of host tissues 
should they undergo necrosis (72,73). Consequently, removal of effete 
neutrophils from sites of infection is crucial to resolution of inflammation. 
Phagocytosis ultimately accelerates apoptosis to promote resolution of the 
inflammatory response and return the immune system to quiescence (Fig. 3).  
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Macrophages recognize and remove the effete neutrophils through a process 
called efferocytosis (52,74). Most invading microorganisms are eliminated by the  
       
 
Figure 3. Two possible outcomes of the interaction of PMNs with 
bacteria.  On one hand, bacteria (pink spheres) are ingested, activate PMNs 
and are killed, and this process ultimately triggers PMN apoptosis and the 
removal of these cells by macrophages (Efferocytosis).  This phenomenon 
leads to the resolution of the inflammatory response (RESOLUTION).  
Alternatively, bacterial pathogens (yellow spheres or red particles) are 
ingested and either delay normal PMN apoptosis and turnover or cause PMN 
lysis.  Typically, these processes facilitate survival of bacteria and thereby 
promote disease (DISEASE).  Reprinted with permission from J. Mol. Med. 
(52). 
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oxygen-independent and oxygen-dependent neutrophil killing mechanisms 
described above. Nonetheless, several bacterial pathogens, including S. aureus, 
are known to evade neutrophil-mediated killing. Pathogens alter neutrophil 
function or survival to evade the innate immune system and thereby promote 
disease. As depicted in Fig. 3, some ingested S. aureus survive within the  
neutrophil phagosome and eventually cause destruction of the leukocyte (75-77). 
Notably, CA-MRSA strains have enhanced capacity to cause destruction of 
neutrophils compared to representative HA-MRSA strains (78). These findings 
provide support to the idea that the most prominent CA-MRSA strains are highly 
virulent as a result of enhanced ability to escape the antimicrobial activity of 
neutrophils following phagocytosis.  
S. aureus produces many molecules that potentially contribute to evasion 
of the innate immune system, including pore-forming toxins that permeabilize 
leukocyte plasma membranes (55,79-81). PVL is one such pore-forming toxin 
and is present in USA300, USA400, and other S. aureus strains that are a 
prominent cause of CA-MRSA infections (52,82). For this reason, significant 
effort has been made by the infectious disease community to elucidate the role (if 
any) PVL has in CA-MRSA pathogenesis (52,82).  
 
1.2 Panton-Valentine leukocidin 
 
1.2.1 Panton-Valentine leukocidin (PVL), a  bicomponent pore-forming toxin 
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The observation that PVL is associated with the major CA-MRSA lineages 
suggests that the toxin may enhance strain virulence or promote enhanced 
transmission (30,39, 83,84). Characterization of the cytolytic activity of PVL 
began in 1932 (as described by Panton and Valentine) (85), and thus, PVL was 
present in S. aureus long before the emergence of CA-MRSA. Studies published 
in 2002 indicate PVL is associated with fatal S. aureus necrotizing pneumonia, 
usually with antecedent influenza (83). These findings, coupled with the 
coincident emergence of CA-MRSA worldwide, renewed interest in PVL as a 
major S. aureus virulence factor. More recently, studies have confirmed an 
association of community-associated S. aureus pneumonia (MRSA and 
methicillin-susceptible S. aureus or MSSA) with antecedent influenza or an 
influenza-like illness (86-88). The molecular basis for severe S. aureus 
pneumonia following influenza remains unknown. 
 PVL consists of two subunits, LukS-PV and LukF-PV, both of which are 
secreted as water soluble monomers. The crystal structure of LukF-PV (89) and 
LukS-PV (90) has been solved and each subunit has three regions, the beta-
sandwich, the rim, and the folded stem. The LukS-PV subunit binds to the 
surface of rabbit and human neutrophils, monocytes, and macrophages (56-59). 
Following LukS-PV binding, a hypothetical pre-pore octomer is formed on the 
PMN plasma membrane with both subunits present in a 1:1 ratio (Fig. 4). At this 
point, the rim regions of LukF-PV and LukS-PV interact with the neutrophil 
plasma membrane. Large variations in conformation between the two subunits 
are present in the rim (90). Presumably, functional differences between the two 
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PVL subunits are determined by variances in the rim domain. Complete pore-
formation is accomplished by extension of the stem region of both subunits 
through the plasma membrane, forming a beta-barrel (Fig. 4) (89-93).  
Genes encoding PVL, lukS-PV and lukF-PV, are acquired by horizontal gene 
transfer via 
bacteriophage such as 
phiSA2usa and the 
subunits are co-
transcribed as an operon 
(94,95). A recent study 
reported the entire 
nucleotide sequence of  
lukS/F-PV prophages 
from 114 clinical MRSA 
isolates and identified 
two insertion sites in the 
S. aureus genome (Ins1 
and Ins2) (96). The 
insertion sites are 
singularly present and 
either Ins1 or Ins2 occur in specific MRSA lineages. The PVL nucleotide 
sequence is highly conserved and one genetic polymorphism in lukS-PV results 
in a nonsynonymous amino acid change in LukS-PV. Variants containing an 
Figure 4. Proposed 
mechanism for PVL 
pore formation. A) 
LukF-PV (red oval) and 
LukS-PV (tan oval) are 
secreted as soluble 
monomers. B) LukS-PV 
binds to an unidentified 
surface molecule/ 
receptor on the surface 
of myeloid cells, 
including neutrophils or 
PMNs. C) PVL subunits 
associate in a 1:1 ratio 
until eight subunits form 
a hypothetical pre-pore 
on the myeloid cell 
surface. D) The stem 
region of each subunit 
extends through the 
plasma membrane to 
form an octomeric beta-
barrel pore. 
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arginine (R variant) or a histidine (H variant) are segregated into specific 
geographic regions. USA300 expresses the R variant, and therefore this variant 
is prominent in the US (97). Studies comparing the interaction of PMNs with R 
and H variants of PVL determined that this amino acid substitution has no impact 
on PVL activities that are described in greater detail below (98,99). 
 
1.2.2 Panton-Valentine Leukocidin (PVL) and human neutrophil interaction 
 The potential for PVL to alter neutrophil function or cause cytolysis is of 
particular interest because PMNs represent the first line of host defense against 
S. aureus infection (60,61,81). Lytic activity of PVL is concentration-dependent 
(58,100-102) and a concentration threshold of PVL must be reached for lysis of 
PMNs to occur. Levels of the toxin below this concentration threshold, estimated 
at 0.2-6 nM, are sublytic (100). Neutrophils exposed to sublytic levels of purified 
PVL exhibit numerous cellular responses that require the presence of both PVL 
subunits. A Ca2+ influx that requires extracellular calcium precedes the formation 
of pores in the plasma membrane (58,59). These two events, Ca2+ influx and 
pore formation, are both mediated by PVL; however, they are induced by distinct 
cellular mechanisms (103). PMNs exposed to sublytic levels of PVL in the 
presence of Ca2+ release several proinflammatory molecules, such as interleukin-
8 (IL-8) and leukotreine B4 (62,104-106). Transcription of IL-8 is upregulated 
following incubation of PMNs with sublytic concentrations of PVL (105). These 
findings support the notion that the presence of Ca2+ is essential for PVL-
mediated release of proinflammatory molecules from human neutrophils. Further, 
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Ca2+ entry into the host cell requires exposure of neutrophils to both PVL 
subunits (90,92). PVL also induces granule exocytosis, thereby releasing 
myeloperoxidase, lysozyme, and beta-glucuronidase into the extracellular space 
(106,107). Although granule exocytosis is consistent with PMN priming, PVL 
alone causes limited production of ROS by human neutrophils (106,108). 
However, neutrophils incubated with PVL and then activated with fMLP released 
3-4 times more ROS compared to neutrophils exposed to PVL alone (108). This 
observation indicates that sublytic levels of PVL prime neutrophils for enhanced 
activation by a secondary stimulus. 
Downstream signal transduction pathways induced or inhibited by the 
interaction of neutrophils with PVL remain largely uncharacterized, although a G-
protein coupled receptor has been previously implicated in the process (109). 
The finding that PVL oligomers associate with neutrophil lipid rafts coupled with 
the observation that inhibition of protein tyrosine kinases decreases PVL-
mediated IL-8 release, supports the notion that PVL triggers neutrophil signal 
transduction (105,110).  
 
1.3 Contribution to the field 
 
Although the lukS/F-PV operon is present in many strains that cause CA-
MRSA infections including the epidemic USA300 clone (39,84), the finding is not 
universal. In addition, multiple studies indicate that the presence of PVL is not a 
primary determinant of the clinical outcome of S. aureus infections (111-114). 
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Bae et al. actually found that patients with PVL-positive infections were more 
likely cured after treatment compared to those with PVL-negative infections 
(113). These findings highlight the need to re-evaluate the role played by PVL 
during S. aureus infection.  
PVL-positive strains express differential amounts of PVL during growth in 
vitro or in vivo (115-118). Human abscesses caused by PVL-positive strains were 
analyzed for presence of PVL and expression of 0.27-2 µg/ml of PVL was 
detected in 15 samples (117). A subsequent study screened 72 methicillin-
sensitive and methicillin-resistant clinical specimens (lukS/F-PV-positive) for PVL 
expression (118). Eighty-six percent of the lukS/F-PV-positive isolates (62/72 
samples) secreted 0-3 µg/ml of PVL during infection. Thus, it is unlikely that a 
concentration of PVL necessary for cytolysis is attained in vivo during infection, 
except perhaps at the focus of infection.  
The overarching objective of my dissertation research is to better 
understand the role played by PVL during the interaction of CA-MRSA with the 
host. One hypothesis is that PVL causes cytolysis of PMNs, thereby enhancing 
S. aureus virulence. As a step toward testing this hypothesis, we evaluated 
human neutrophil pore formation and cytolysis using USA300 and USA400 
culture supernatants from multiple S. aureus growth conditions in vitro or purified 
PVL, and determined whether there was a direct correlation between pore 
formation and subsequent cytolysis (Chapter 2).  
The level of PVL produced in vivo may not be sufficient to cause lysis of 
PMNs. However, it is possible that sublytic levels of PVL alter the host response 
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to infection. For example, animal infection studies with wild-type (WT) and 
isogenic lukS/F-PV deletion strains suggest that PVL increases the innate 
immune response, and thereby augments clearance of infection. We hypothesize 
that PVL primes PMNs for enhanced function, thus altering the outcome of CA-
MRSA infection. To test this hypothesis, we investigated the ability of sublytic 
concentrations of PVL to prime human neutrophils for enhanced function 
(Chapter 3). In addition, we assessed global changes in PMN gene expression 
and identified proinflammatory molecules released from neutrophils following 
exposure to a sublytic concentration of PVL (1 nM). These results, in combination 
with previous studies, suggest PVL functions primarily as an immune modulatory 
agent rather than a cytolytic toxin. 
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CHAPTER TWO 
RELATIVE CONTRIBUTION OF PANTON-VALENTINE LEUKOCIDIN TO PMN 
PLASMA MEMBRANE PERMEABILITY AND LYSIS CAUSED BY USA300 AND 
USA400 CULTURE SUPERNATANTS 
2.1 Abstract 
Panton-Valentine leukocidin (PVL) is a cytolytic toxin associated with 
severe community-associated methicillin-resistant Staphylococcus aureus (CA-
MRSA) infections.    However, the relative contribution of PVL to host cell lysis 
during CA-MRSA infection remains unknown.  Here we investigated the relative 
contribution of PVL to human polymorphonuclear leukocyte (PMN) plasma 
membrane permeability and lysis in vitro by using culture supernatants from wild-
type and isogenic lukS/F-PV-negative (Δpvl) USA300 and USA400 strains.  
Using S. aureus culture conditions that favor selective high production of PVL 
(CCY media), there was on average more PMN plasma membrane permeability 
and cell lysis caused by supernatants derived from wild-type strains compared 
with those from Δpvl strains.  Unexpectedly, plasma membrane permeability did 
not necessarily correlate with ultimate cell lysis.  Moreover, the level of pore 
formation caused by culture supernatants varied dramatically (e.g., range was 
0.32–99.09% for wild-type USA300 supernatants at 30 min) and was not 
attributable to differences in PMN susceptibility to PVL among human blood 
donors.  We conclude that PMN pore formation assays utilizing S. aureus culture 
supernatants have limited ability to estimate the relative contribution of PVL to 
pathogenesis (or cytolysis in vitro or in vivo), especially when assayed using 
culture media that promotes selective high production of PVL.           
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2.2 Introduction 
 
Staphylococcus aureus is a significant cause of human infections worldwide.  
The organism also acquires antibiotic resistance readily and methicillin resistant 
S. aureus (MRSA) are endemic in healthcare settings in many countries (1).  
Prior to the early 1990s, MRSA infections were almost exclusively associated 
with healthcare settings and disease occurred in individuals with known risk 
factors for infection.  Although healthcare-associated MRSA (HA-MRSA) remain 
a major problem, MRSA are a leading cause of community-associated bacterial 
infections in some industrialized countries, such the United States and Canada 
(2).  These so-called community-associated MRSA (CA-MRSA) infections occur 
in seemingly healthy individuals with no predisposing risk factors for infection, 
suggesting that they have enhanced virulence by comparison.  Experimental 
data with animal infection models using CA-MRSA strains provides strong 
support to this notion (3,4).  The molecular basis for the enhanced virulence 
phenotype of CA-MRSA strains, especially USA300 and USA400, which 
predominate in North America, is incompletely defined.       
A methicillin-resistance element known as staphylococcal cassette 
chromosome (SCC) mec type VI (SCCmecIV) and genes encoding Panton-
Valentine leukocidin (PVL) (lukS-PV and lukF-PV) are elements common among 
many CA-MRSA strains worldwide (2).  PVL is a cytolytic toxin composed of 
LukF-PV and LukS-PV subunits that assemble into an octameric pore on the 
surface of myeloid cells, including polymorphonuclear neutrophils (PMNs).  
Although sublytic concentrations of PVL cause PMN apoptosis (5), sufficient pore 
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formation causes a change in the cellular levels of normally impermeable solutes, 
such as K+, which can lead to osmotic cell lysis (necrosis) (6,7).  The leukocidin 
is linked by epidemiology to specific types of severe skin infection and severe 
necrotizing pneumonia (8,9).  Inasmuch as PMNs are the primary cellular 
defense against S. aureus infections, molecules such as PVL that have potential 
to eliminate neutrophils and/or alter neutrophil function might therefore contribute 
to pathogenesis.  USA300 and USA400 strains contain genes encoding multiple 
pore-forming toxins with high homology or identity to lukS-PV and lukF-PV.  The 
relative contribution of these molecules to CA-MRSA virulence has not been 
determined, although this matter has been the subject of intense research over 
the past several years (10-15).  In addition, high expression of PVL in vitro 
appears optimal only during growth in specific S. aureus culture media, which 
may limit the utility of such assays in predicting activity in vivo.     
As a step toward understanding the relative contribution of PVL to lysis of 
PMNs caused by USA300 and USA400 strains, we evaluated human PMN 
plasma membrane permeability and lysis using culture supernatants from 
multiple S. aureus growth conditions in vitro.  
 
2.3 Materials and Methods 
2.3.1 Bacterial strains and culture. 
USA300 (LAC and SF8300) and USA400 (MW2) wild-type and isogenic 
lukS-PV and lukF-PV deletion strains (LACΔpvl, SF8300Δpvl, and MW2Δpvl) 
were described previously (11,12). Bacteria from frozen, low passage stocks 
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were cultured overnight in trypticase soy broth (TSB, Difco, Detroit Michigan), 
CCY medium (3% wt/vol yeast extract, 2% Bacto-Casamino acids, 2.3% sodium 
pyruvate, 0.63% Na2HPO4, and 0.041% KH2PO4, pH 6.7), or 100% pooled 
human serum. Overnight cultures were either used to generate supernatants 
directly or diluted 1:200 into fresh culture media and incubated for 8 h (to early 
stationary phase of growth, OD600 = 0.75) with shaking at 225 rpm at 37°C.  
Bacteria were removed from the culture media by centrifugation (2061 g for 10 
min at 4°C). Culture supernatants were sterilized by filtration and stored in 
aliquots at -80°C for future use.  
 
2.3.2 Purification of PVL subunits from USA300 culture medium. 
LukS-PV and LukF-PV subunits were purified from culture supernatants of 
USA300 strain LAC containing deletion of hlgA, hlgB, and hlgC (LACΔhlgABC) 
as described previously (16,17), but with a few modifications.  Briefly, 
LACΔhlgABC was cultured to early stationary phase of growth in CCY medium 
and cultures were centrifuged to remove bacteria.  Following sterile filtration, 
supernatant proteins were precipitated with ammonium sulfate (80% saturation) 
at 4°C for 16 h. Precipitates were centrifuged at 15000 g for 20 min at 4°C and 
resuspended in Buffer 1 (30 mM sodium phosphate buffer, pH 6.5).  Proteins 
were dialyzed against Buffer 1 for 5 h, subjected to ion-exchange 
chromatography using a HiPrep 16/10 CM FF sepharose column (GE Healthcare 
Life Sciences, Piscataway, New Jersey), and eluted with a linear gradient of 0 to 
0.5 M NaCl in Buffer 1.  Fractions containing LukS-PV were subjected to a 
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second round of ion-exchange chromatography using a Mono S 5/50 GL column 
(GE Healthcare Life Sciences) and LukS-PV was eluted with a linear gradient of 
0 to 0.25 M NaCl in Buffer 1. Ammonium sulfate was added to LukF-PV and 
LukS-PV fractions to 1.5 M and these samples were subjected to hydrophobic 
interaction chromatography using a HiTrap Butyl HP column (GE Healthcare Life 
Sciences).   PVL subunits were eluted with a linear gradient of 1.5 to 0 M 
ammonium sulfate and aliquots of each subunit were stored at -80°C in 0.2 M 
NaCl-Buffer 1.  Identity and purity of LukS-PV and LukF-PV were evaluated 
initially by SDS-PAGE and immunoblot analysis, and then by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) at the NIAID Mass 
Spectrometry Unit, Bethesda, Maryland.  
 
2.3.3 Human PMN assays. 
PMNs were isolated from venous whole blood of healthy individuals using a 
published method (18) in accordance with a protocol approved by the NIAID 
Institutional Review Board for Human Subjects.  Each human subject included in 
the study gave informed consent.  Lysis of PMNs was assessed by the release of 
lactate dehydrogenase (LDH) using a Cytotoxicity Detection Kit (Roche Applied 
Sciences, Pleasanton, California) as described previously (3,12).  Culture 
supernatants were thawed on ice and diluted in RPMI 1640 medium (Invitrogen) 
buffered with 10 mmol/l HEPES (RPMI/H, pH 7.2).  PMNs (1 × 106) in 100 µl 
RPMI/H were combined with 100 µl of diluted supernatants in 96-well round-
bottom plates.  Cells were incubated for the indicated times (3-18 h) at 37°C with 
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5% CO2. At designated time points, plates were centrifuged at 587 g for 7 min at 
4°C. Aliquots (100 µl) from each well were transferred to a 96-well flat-bottom 
plate and percent LDH release was determined according to the manufacturer’s 
instructions.    
 PMN plasma membrane permeability (formation of plasma membrane 
pores) was measured by ethidium bromide (EtBr) uptake as described essentially 
by Gauduchon et al. (19). Culture supernatants were diluted in RPMI/H as 
described above and mixed 1:1 with human PMNs (1 × 106) and 4 µmol of EtBr 
as described (19). At designated time points, PMNs were analyzed by flow 
cytometry (FACSCalibur, BD Biosciences, San Jose, California). 
 In some experiments, PMNs were incubated with 1 nM purified PVL 
(LukS-PV + LukF-PV) or individual PVL subunits and EtBr and LDH release were 
determined as described above.   
 
2.3.4 SDS-PAGE and LukS/F-PV Western Blots. 
Proteins present in CCY and TSB culture supernatants were resolved by 
12.5% SDS-PAGE and transferred to nitrocellulose membranes using an iBlot 
Dry Blotting System (Invitrogen, Carlsbad, California).  Nitrocellulose membranes 
were blocked in Tris-buffered saline containing 10% goat serum and 1% Tween 
20 overnight.  Immunoblots were rotated for 1 h at ambient temperature in diluted 
blocking buffer containing affinity-purified rabbit IgG specific for a peptide region 
of LukF-PV or LukS-PV (GenScript USA Inc., Piscataway, New Jersey) or rabbit 
IgG specific for Hla (Sigma-Aldrich, St. Louis, Missouri).  Membranes were 
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washed three times for 10 min each in wash buffer (250 mM NaCl, 10 mM 
HEPES, 0.2% Tween-20, pH 7.4) and then incubated with peroxidase-
conjugated anti-rabbit donkey IgG secondary antibody for 1 h.  Membranes were 
washed twice in wash buffer and once in Tris-buffered saline and LukF-PV and 
LukS-PV were visualized using enhanced chemiluminescence (SuperSignal 
West Pico, Fisher Scientific, Pittsburg, Pennsylvania).  LukS-PV was quantified 
by densitometry with a standard curve of purified LukS-PV using Quantity One 
Software (Bio-Rad Laboratories, Hercules, California).  There was 0.8 µg/ml, 3.8 
µg/ml, and 3.6 µg/ml LukS-PV produced by MW2, LAC, and SF8300 in TSB at 
early stationary phase of growth, and 0.9 µg/ml, 2.0 µg/ml, and 1.2 µg/ml for 
these strains after overnight growth in the same media.  By comparison, there 
was 30.6 µg/ml, 100.4 µg/ml, and 101.4 µg/ml LukS-PV produced by MW2, LAC, 
and SF8300 in CCY at early stationary phase of growth, and 31.8 µg/ml, and 
32.8 µg/ml for LAC and SF8300 after overnight growth in CCY.  PVL subunits 
were frequently not detectable in MW2 culture supernatants after overnight 
growth in CCY.   
 
2.3.5 S. aureus genomic DNA extraction. 
  USA300 strain LAC was cultured in TSB to early stationary phase of 
growth and then bacteria were pelleted by centrifugation as described above. 
Bacteria were resuspended in 450 µl of P1 buffer (Plasmid Prep Kit, Qiagen, Inc., 
Valencia, California), to which 50 µl of 1 mg/ml lysostaphin was added.  Samples 
were incubated for 3 h at 37°C to complete lysis.  After lysis of bacteria, DNA 
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was isolated using the DNeasy Tissue Kit (Qiagen) and as recommended by the 
manufacturer. 
 
2.3.6 RNA extraction and TaqMan Real-Time RT-PCR analysis. 
S. aureus strains were cultured as indicated and lysed using FastPrep (FP 
120, MP Biomedicals, Solon, Ohio). RNA isolation was completed using the 
RNeasy Mini Prep Kit (Qiagen) as described previously (20). Each strain and 
growth condition was assayed in triplicate by TaqMan real-time RT-PCR analysis 
using an ABI 7500 thermocycler (Applied Biosystems Inc., Foster city, California).  
Change in expression of target genes was determined by comparison to known 
quantities of S. aureus genomic DNA and relative expression of the 
housekeeping gene gyrB. The primer-probe sequences are as follows: gyrB 
forward primer 5’-CAAATGATCACAGCATTTGGTACAC-3’, gyrB probe 5’-AATC 
GGTGGCGACTTTGATCTAGCGAAAG-3’, gyrB reverse primer 5’-CGGCATCAG 
TCATAATGACGAT-3’, LukF-PV forward primer 5’-TTGCTTTTGCTATCCAATAC 
AGTTG-3’, LukF-PV probe 5’-TGCAGCTCAACATATCACACCTGTAAGT-3’, 
LukF-PV reverse primer 5’-TCGGAATCTGATGTTGCAGTTG-3’, LukS-PV 
forward primer 5’-AATAACGTATGGCAGAAATATGGATGT- 3’, LukS-PV probe 
5’-ACTCATGCTACTAGAAGAACAACACACTATGG-3’, LukS-PV reverse primer 
5’-CAAATGC GTTGTGTATTCTAGATCCT-3’. 
 
2.3.7 Statistical analyses. 
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Data were evaluated using a paired Student’s t-test (GraphPad Prism 5, 
GraphPad Software, Inc., San Diego, California).  PMN lysis data in Fig. 7 from 
wild-type CCY culture supernatants were also compared using a one-way 
analysis of variance (ANOVA) and Tukey’s posttest. 
 
2.4 Results 
2.4.1 Membrane pore formation caused by S. aureus culture supernatants is 
highly variable.  
To estimate the relative contribution of PVL to formation of membrane 
pores in leukocytes, we evaluated the ability of culture supernatants from 
USA300 and USA400 wild-type and Δpvl strains to promote uptake of ethidium 
bromide (EtBr) by human PMNs (Fig. 5 and 6).  EtBr uptake has been used 
widely to estimate PVL-mediated membrane pore formation with human 
neutrophils, as the diameter of the pores (2–2.4 nm or 20-24 angstroms) allow 
free diffusion of EtBr (0.8 nm or 8 angstroms) into cells (21-26). We first tested 
pore-forming capacity of CCY culture supernatants, since S. aureus can produce 
up to 100 milligrams of PVL per liter of CCY media (16,27,28).  There was time-
dependent formation of PMN membrane pores with all growth conditions and 
supernatant concentrations (dilutions) tested (Fig. 5 and 6).  On average, there 
was significantly more uptake of EtBr by PMNs exposed to wild-type culture 
supernatants compared with those from Δpvl strains (Fig. 5 and 6).   However, in 
many of the individual assays, especially those in which PMNs were exposed to 
culture supernatants for 30 min, the level of pore formation was comparable  
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Figure 5. Permeability of PMNs (plasma membrane pore formation) 
exposed to USA300 and USA400 CCY culture supernatants.  PMNs (1 
× 106) were incubated with a 1:500 dilution of CCY media alone (CCY) or 
CCY culture supernatants obtained from growth of S. aureus strains as 
indicated.  Each symbol indicates a separate experiment and/or human 
PMN donor. Different batches of CCY media are indicated by symbol color 
or fill. Black bars indicate the mean percent ethidium bromide (EtBr) uptake 
by PMNs at each time point, A) 5 min. B) 15 min. C) 30 min. *: p ≤ 0.05 vs. 
wild-type (WT; i.e., MW2, LAC, or SF8300); **: p ≤ 0.01 vs. WT; ***: p ≤ 
0.001 vs. WT.  
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Figure 6. Permeability of PMNs exposed to USA300 and USA400 CCY 
culture supernatants.  PMNs (1 × 106) were incubated with a 1:2000 
dilution of CCY media alone (CCY) or CCY culture supernatants obtained 
from growth of S. aureus strains as indicated.  Each symbol indicates a 
separate experiment and/or human PMN donor. Different batches of CCY 
media are indicated by symbol color or fill.  Black bars indicate the mean 
percent ethidium bromide (EtBr) uptake by PMNs at each time point, A) 5 
min. B) 15 min. C) 30 min. *: p ≤ 0.05 vs. wild-type (WT; i.e., MW2, LAC, or 
SF8300); **: p ≤ 0.01 vs. WT; ***: p ≤ 0.001 vs. WT. 
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between wild-type and Δpvl strains (Fig. 5B and C, and Fig. 6C).  We found that 
culture supernatants from bacteria grown in trypticase soy broth (TSB), a 
standard culture medium for S. aureus, had little or no PMN pore-forming 
capacity at the highest concentration used for CCY (1:500 dilution) (data not 
shown).  Membrane pore formation was highly varied using CCY culture 
supernatants (e.g., the range of pore formation was 0.6–99.9% for the MW2 wild-
type strain at 30 min using a 1:500 dilution) (Fig. 5C).  Although there was 
variation in PMN pore formation among individuals using the same batch of 
culture supernatant, some of the observed variation overall was due to 
differences among separate batches CCY media (Fig. 5 and 6, symbol colors 
and fills).   
 
2.4.2 Correlation of membrane pore formation and PMN lysis. 
 Formation of plasma membrane pores by PVL and other two-component 
toxins of S.aureus is generally considered to result in host cell lysis.  To test this 
notion, we evaluated the ability of culture supernatants from USA300 and 
USA400 wild-type and Δpvl strains to cause release of lactate dehydrogenase 
(cell lysis) from human PMNs over time (Fig. 7 and 8).  PMN lysis caused by 
exposure to CCY or TSB culture supernatants from USA300 and USA400 strains 
was time and concentration dependent (Fig. 7 and 8).  In addition, there was 
significantly more lysis of PMNs exposed to wild-type CCY culture supernatants 
compared with those from Δpvl strains at the highest concentrations tested  
(1:250 and 1:500 dilutions) (Fig. 7A and B).  In contrast, there was no difference 
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Figure 7. PMN lysis after exposure to USA300 or USA400 CCY 
culture supernatants. PMNs (1x106) were incubated for 3, 6, 9, or 18 
h with the indicated dilution of culture supernatant. Cell lysis was 
measured by LDH release as described in Materials and methods. Bars 
indicate mean ± SD of 8-11 PMN donors; *p ≤ 0.05 vs. WT; #p ≤ 0.05 
using a one-way analysis of variance (ANOVA) with a Tukey’s posttest. 
A) 1:250 dilution. B) 1:500 dilution. C) 1:2000 dilution. PVL ‘‘+’’ 
indicates wild-type lukS/F-PV positive strain; PVL ‘‘-’’ indicates isogenic 
lukS/F-PV negative strain. CCY alone caused no significant lysis of 
human PMNs over the 18 h culture period (range was 0-1.5% for 3-18 
h, n = 4 PMN donors). 
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Figure 8. PMN lysis after exposure to USA300 or USA400 TSB culture 
supernatants. PMNs (1x106) were incubated for 3, 6, 9, or 18 h with the 
indicated dilution of culture supernatant. Cell lysis was measured by LDH 
release as described in Materials and methods. Bars indicate mean ± SD of 
6 PMN donors for panels A-C and 4-6 PMN donors for panel D; *p ≤ 0.05 
vs. WT. A) 1:10 dilution. B) 1:50 dilution. C) 1:100 dilution. D) 1:500 dilution. 
PVL ‘‘+’’ indicates wild-type lukS/F-PV-positive strain; PVL ‘‘-’’ indicates 
isogenic lukS/F-PV negative strain. TSB alone caused no significant lysis of 
human PMNs over the 18 h culture period (range was 0-0% for 3-18 h, n = 
4 PMN donors). 
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in PMN lysis between TSB culture supernatants from wild-type and Δpvl strains  
 (e.g., PMN lysis was 87.1 ± 14.5 and 87.5 ± 9.1% after a 3-h exposure to LAC 
wild-type and Δpvl TSB supernatants from overnight culture (1:10 dilution) (Fig. 
8).   
Although there was some concordance between pore formation and cell 
lysis assays, especially with CCY culture supernatants from wild-type strains, 
there were noted differences.  First, at the lowest concentration of CCY culture 
supernatant used (1:2000 dilution), there was little or no correlation between pore 
formation and PMN lysis (compare Fig. 6C and 7C).  Further, PMN pore 
formation was at or near 100% after 30 min of exposure to the highest 
concentration of CCY culture supernatants from Δpvl strains (Fig. 4C), whereas 
the corresponding cell lysis was < 10% at all time points tested (up to 18 h) (Fig. 
7B).  We also note that culture supernatants from the MW2 wild-type strain often 
caused significantly less lysis than those from USA300 wild-type strains (Fig. 7).  
Collectively, the data indicate that pore formation caused by S. aureus culture 
supernatants does not necessarily correlate with (or result in) cell lysis.   
Inasmuch as in vitro culture media (CCY and TSB) are not likely 
representative of culture conditions during infection in humans, we tested the 
ability of normal human serum to promote production and activity of S. aureus 
cytolytic toxins.  In contrast to CCY and TSB, human serum used as culture 
media for USA300 and USA400 strains had zero capacity to cause PMN lysis at 
all concentrations tested (1:1–1:100 dilutions).  This finding cannot be explained 
by the absence of bacterial growth in serum, since S. aureus grew reasonably 
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well in this culture substrate (Fig. 10H).  Rather, the lack of PMN cytolysis in 
serum culture supernatants may be due to the ability of serum lipoproteins and 
apolipoprotein B to inhibit agr signaling (29), a regulator of expression of multiple 
virulence factors, and thus, synthesis and secretion of PVL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.3 Cytolytic effects of purified PVL and human blood donor variability.  
We next used PVL subunits purified from USA300 to determine whether 
the variation in PMN pore formation noted in the assays with culture supernatant 
was due to individual susceptibility to PVL (Fig. 9). Neither subunit alone caused 
Figure 9. Purified PVL 
causes relatively 
consistent levels of 
plasma membrane pore 
formation in human 
PMNs. A-C) PMNs 
(1x106) were incubated 
with 1 nM of purified PVL 
subunits (LukF-PV or 
LukS-PV) or the 
combination of both 
subunits for the indicated 
times. Each symbol color 
indicates a separate 
human PMN donor (n = 
9). Black bars indicate the 
mean percent ethidium 
bromide (EtBr) uptake by 
PMNs at each time point. 
D) PMNs (1x106) were 
incubated with 1 nM of 
purified PVL subunits 
(LukF-PV or LukS-PV) 
and PMN lysis was 
measured by release of 
LDH as described in 
Materials and methods. 
Red bar indicates mean ± 
SD of 4 PMN donors. 
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formation of membrane pores in human PMNs.  By comparison, there was time-
dependent uptake of EtBr using the combination of 1 nM LukF-PV+LukS-PV (Fig. 
9).  There was far less variation in the capacity of purified PVL to permeabilize 
human PMNs compared with culture supernatants (EtBr uptake was 76.1–96.1% 
at 30 min using purified PVL subunits) (Fig. 9C).  Despite the high level of pore 
formation, there was essentially no corresponding PMN lysis at this time point 
(LDH release was 0.7 ± 0.7% at 30 min, n = 4 PMN donors) (Fig. 9D).  These 
data indicate that the variation noted in assays with culture supernatants is 
largely independent of differences in PMN donor susceptibility to PVL.     
 
2.4.4 Levels of lukS-PV and lukF-PV transcript and corresponding PVL protein 
subunits are highly varied depending on in vitro growth conditions. 
 We next compared levels of lukS-PV and lukF-PV (lukS/F-PV) transcripts 
and corresponding protein subunits following culture of USA300 and USA400 
strains in CCY, TSB, or human serum (Fig. 10A–H).  Compared with strains 
cultured in TSB or human serum, there was more lukS/F-PV transcript made by 
LAC and MW2 following culture in CCY (Fig. 10A–C).   In accordance with these 
findings, more LukS-PV and LukF-PV accumulated in CCY culture media 
compared with that in TSB (Fig. 10D–F).  Most notably, there was selective high 
production of PVL in CCY media, since the level of alpha-hemolysin (Hla, 
another agr-regulated cytolytic toxin) present in CCY was not increased relative 
to that in TSB culture supernatants (Fig. 10F).   Using a purified PVL standard, 
we estimate that USA300 strains accumulated ~3–4 µg/ml of LukS-PV in TSB  
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Figure 10. Impact of culture media on lukS-PV and lukF-PV transcript 
levels and protein subunit secretion. A-C) Relative expression of lukS-
PV and lukF-PV transcripts during bacterial growth as indicated. Different 
colors or fill indicate separate batches of CCY. Symbols are the mean of 
triplicate TaqMan samples. Black bars indicate mean of each strain 
group. A) Growth in CCY. B) Growth in TSB. C) Growth in normal human 
serum. D) PVL secretion during growth in CCY (upper panel) or TSB 
(lower panel). E) Longer exposure of the immunoblot shown in the lower 
panel of D.  Results in panels D and E are representative of 3 
experiments. F) Immunoblot of PVL subunits (1.75 µl of CCY or TSB 
culture supernatants) and Hla (35 µl of CCY or TSB culture supernatants) 
produced in CCY or TSB culture at early stationary phase of growth.  
Results are representative of 2 experiments.  G) Immunoblot of PVL 
subunits secreted during MW2 (USA400) and SF8300 (USA300) growth 
in different batches of CCY. H) Growth of LAC (USA300) in CCY, TSB, 
and normal human serum.  
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and ~100 µg/ml in CCY at early stationary phase of growth (see Materials and 
Methods for details).  The finding that there was little or no detectable lukS/F-PV 
transcript made by LAC cultured in human serum (Fig. 10C) is consistent with the 
observation that supernatants from neither USA300 nor USA400 strains cultured  
in human serum caused PMN lysis (data not shown) and that serum lipoproteins 
inhibit agr signal transduction (29). 
There were also strain-dependent differences in lukS/F-PV transcript and 
PVL protein levels.  For example, compared with LAC, there was less lukS/F-PV 
transcript made by MW2 in either CCY or TSB, and there was correspondingly 
less accumulated PVL protein in MW2 culture supernatants (e.g., there was ~42-
fold more lukF-PV transcript made by LAC at early stationary phase of growth in 
CCY compared with MW2) (Fig. 10).  These findings are compatible with 
differences noted between USA300 and USA400 strains in recent studies by 
Montgomery et al. (30).  Although differences in lukS/F-PV transcript and PVL 
protein levels may account in part for the differences in PMN lysis observed  
between MW2 and USA300 CCY culture supernatants (Fig. 7), there is limited 
correlation of transcript and protein levels with pore-forming capacity of the 
strains, which was comparable (Fig. 5 and 6).  Taken together, these data 
provide strong support to the notion that factors present in culture supernatants 
other than PVL are sufficient to cause formation of membrane pores in human 
PMNs.     
 
2.5 Discussion 
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It has long been known that PVL is cytolytic for myeloid cells and therefore, a 
putative virulence molecule of S. aureus (31-34).  Finck-Barbançon et al. 
provided direct evidence that PVL is a pore-forming toxin and reported that 
membrane pore size is dictated by ionic conditions of the extracellular 
environment (21).  Notably, these studies set a precedent for using an ethidium 
bromide uptake assay to evaluate membrane permeability following exposure to 
PVL (21). Plasma membrane pores that allow ethidium bromide uptake by PMNs 
are in general considered to result ultimately in cell lysis through osmotic 
imbalance (6,7,21,25).  The assay or modifications thereof have since been used 
to evaluate precise kinetics of pore formation caused by purified or recombinant 
PVL (19,23), pore-forming capacity of heterologous combinations of LukS and 
LukF proteins (PVL, gamma-hemolysin, and LukD and LukE subunits) (24), the 
ability of intravenous immunoglobulin or specific anti-PVL antibody to block pore 
formation (19),  and to estimate the relative contribution of PVL to cytolytic 
capacity of S. aureus culture supernatants (12,19,35).  
We reported previously that PMNs exposed to supernatants from Δpvl strains 
cultured overnight in YCP media, a culture media similar in composition to CCY, 
promoted uptake of EtBr at levels comparable to the wild-type strains (12).  
Although these findings were unexpected, especially given the high level of PVL 
produced in either YCP or CCY media (up to 20% of the protein in culture filtrates 
(27)), they are perhaps explained by the high variation reported here as intrinsic 
to the pore formation assay.  Some of the variation is due to differential levels of 
lukS/F-PV transcript and PVL protein levels produced in separate batches of the 
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same media (Fig. 10A and G).  Most importantly, there is not a direct correlation 
between EtBr uptake and LDH release by human PMNs, which is a widely 
accepted determination of cell lysis.   
There is clearly more PMN lysis caused by CCY supernatants from wild-type 
USA300 strains compared to that from Δpvl mutant strains (not observed with 
MW2 wild-type and Δpvl strains), but this difference is presumably due to the 
very high concentration of PVL in CCY culture supernatants.  Therefore, diluting 
CCY culture media to obtain PVL-specific cytolysis is in essence similar to using 
purified PVL, since such an approach decreases the level of other S. aureus 
molecules that would have otherwise contributed to pore formation and/or lysis.  
This notion is consistent with the observation that there are limited differences in 
PMN pore formation between wild-type and Δpvl strains using lower dilutions of 
CCY culture supernatant (Fig. 5C), and the finding that PVL is selectively 
overproduced in CCY media relative to Hla (Fig. 10F).   Furthermore, the 
concentration of PVL produced in TSB (3-4 µg/ml), which is more representative 
of that found in human abscesses (0.3–1.8 µg/ml) (36), is perhaps a better gauge 
of the relative contribution of PVL to PMN lysis caused by S. aureus.  In any 
case, factors present in TSB culture supernatants other than PVL, such as alpha-
type phenol-soluble modulins (37) and/or gamma-hemolysin (17), were sufficient 
to cause lysis of human PMNs (Fig. 8).    
We conclude that the PMN pore formation assays described herein, although 
appropriate to evaluate effects of purified PVL or estimate whether cytolytic 
59 
 
capacity exists in culture supernatant, have limited ability to estimate the relative 
contribution of PVL to membrane pore formation or PMN lysis in vivo.           
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CHAPTER THREE 
SUBLYTIC CONCENTRATIONS OF STAPHYLOCOCCUS AUREUS PANTON-
VALENTINE LEUKOCIDIN (PVL) ALTER HUMAN NEUTROPHIL GENE 
EXPRESSION AND FUNCTION 
3.1 Abstract 
Community-associated methicillin-resistant Staphylococcus aureus (CA-
MRSA) infections are often caused by strains encoding Panton-Valentine 
leukocidin (PVL). PVL causes lysis of neutrophils and other myeloid cells in vitro, 
a function considered widely as the primary means by which PVL might 
contribute to disease. However, at sublytic concentrations PVL can function as a 
neutrophil agonist. To better understand this phenomenon, we investigated the 
ability of PVL at sublytic concentrations (1 nM) to alter human neutrophil function 
and survival. PVL-primed neutrophils for enhanced release of superoxide 
following activation by fMLP, caused upregulation of CD11b, and accelerated 
apoptosis. Priming of neutrophils with other agonists such as IL-8 or GM-CSF 
altered the ability PVL to cause formation of pores in the plasma membrane. 
Microarray analysis revealed significant changes in the human PMN 
transcriptome following exposure to PVL, including upregulation of STAT3, 
SOCS3, CXCL1, and CXCL2. Consistent with microarray data myeloperoxidase, 
IL-8, IL-6, VEGF, TNFR2, and IL-1RA were released from neutrophils after 
stimulation with PVL. We conclude that exposure of human PMNs to sublytic 
concentrations of PVL elicits a proinflammatory response that is regulated in part 
at the level of gene expression. We propose that PVL-mediated priming of 
neutrophils enhances the host innate immune response. 
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3.2 Introduction 
 Staphylococcus aureus is a Gram-positive bacterium that causes a 
significant number of infections worldwide (1). Methicillin-resistant S. aureus 
(MRSA) is currently a leading contributor to hospital-acquired (HA-MRSA) 
infections (2,3). MRSA infections that occur outside of hospital settings, known 
as community-associated MRSA (CA-MRSA) infections, were reported in the 
early 1990s and became epidemic in the United States and Canada (4-6). In 
contrast to HA-MRSA, CA-MRSA causes infections in individuals with no known 
risk factors for infection. The ability of these strains to cause disease in otherwise 
healthy individuals suggests that they have enhanced virulence compared to 
traditional HA-MRSA strains. In vitro and in vivo work supports this hypothesis (7-
9). Although progress has been made, the molecular basis of the enhanced 
virulence phenotype of CA-MRSA remains incompletely determined. 
 Genes encoding Panton-Valentine leukocidin (PVL) are present in the 
genome of many CA-MRSA strains, including the epidemic USA300 strain (10-
12). PVL consists of two subunits, LukS-PV and LukF-PV, the genes for which 
are transcribed as an operon. It is a cytolytic toxin specific for myeloid cells, 
including polymorphonuclear leukocytes (PMNs or neutrophils). The presence of 
both subunits is required for formation of pores within the PMN plasma 
membrane (13,14). Neutrophils are the most prominent cellular component of the 
innate immune system and thus the primary defense against S. aureus infections 
(15). Therefore, it is possible that PVL contributes to virulence by causing lysis of 
PMNs and other myeloid cells. However, previous studies have shown that 
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cytolysis in vitro requires a concentration of PVL that may not be achieved in vivo 
(16,17). Sublytic concentrations of PVL elicit numerous cellular responses, 
including release of myeloperoxidase (MPO) and chemotactic molecules such as 
interleukin-8 and leukotriene B4 (18-21). PMNs exposed to PVL undergo granule 
exocytosis and produce reactive oxygen species (ROS) following stimulation with 
fMLP (22). These observations suggest that sublytic levels of PVL prime 
neutrophils for enhanced activation by a secondary stimulus. The molecular 
basis for PVL-mediated PMN priming remains unknown.  
PMNs primed with cytokines or proinflammatory molecules produced by 
bacteria have prolonged survival compared to unprimed cells (23-25). By 
comparison, sublytic concentrations of PVL accelerate neutrophil apoptosis (26). 
Therefore, the observation that PVL primes PMNs for enhanced function and 
induces rather than delays apoptosis differentiates PVL-mediated priming from 
that induced by other molecules.  
To elucidate the molecular basis of PVL-mediated PMN priming, we 
measured PMN gene expression following exposure of these cells to sublytic 
concentrations of PVL. In addition, we identified proinflammatory molecules 
secreted by PMNs following exposure to the leukotoxin. Our results provide new 
insight into the role played by PVL during human infection. 
 
3.3 Materials and Methods 
3.3.1 Heat-killed USA300 strain LAC. 
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USA300 strain LAC was cultured overnight in trypticase soy broth (TSB) 
(Difco, Detroit, MI) from frozen bacterial stocks. Overnight cultures were diluted 
1:200 in fresh TSB media and cultured to mid-logarithmic growth phase (O.D.600 
= 0.75) as described (17). Bacteria were centrifuged at 3000 rpm for 10 min, 
washed once with PBS, and centrifuged again to pellet bacteria. The bacterial 
pellet was resuspended in RPMI 1640 meida buffered with 10 mM Hepes and 
boiled at 95 ˚C for 10 min.  
 
3.3.2 Purification of PVL subunits from USA300 culture supernatant. 
PVL subunits (LukF-PV and LukS-PV) were purified from culture 
supernatants of a USA300 hlgABC deletion strain (LACΔhlgABC) as described 
previously (17). Purified LukF-PV and LukS-PV were aliquoted separately and 
stored at -80˚C in 0.2 M NaCl-Buffer 1 (30 mM sodium phosphate buffer, pH 6.5). 
 
3.3.3 Human PMN isolation. 
PMNs were isolated from venous whole blood as previously published 
(27). Each subject gave informed consent prior to participation in the study. Use 
of healthy individuals for collection of blood was approved by the Institutional 
Review Board for Human Subjects, NIAID, NIH. 
 
3.3.4 PMN membrane permeability and lysis assays. 
Formation of plasma membrane pores was measured by uptake of 
ethidium bromide (EtBr) as previously described by Gauduchon et al. (28). 
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Purified PVL subunits (LukF-PV and LukS-PV) were diluted at the desired 
concentrations  in RPMI/H. PVL-mediated pore formation was evaluated by 
incubating human PMNs (1 x 106) with 4 µmol of EtBr and 1 nM, 2 nM, or 5nM 
active PVL for 30 min. LukF-PV and LukS-PV were boiled at 95 ˚C for 10 min to 
produce heat-inactivated PVL (iPVL). iPVL was used as a negative control. EtBr 
uptake was analyzed by flow cytometry (FACSCalibur, BD Biosciences, San 
Jose, CA). 
Human IL-8 and GM-CSF were purchased from eBiosciences (San Diego, 
CA). N-formyl-methionyl-leucyl-phenylalanine (fMLP), phorbol myristate acetate 
(PMA), and lipopolysaccharide (LPS) were purchased from Sigma Aldrich (St. 
Louis, MO). IL-8, GM-CFS, fMLP, PMA, and LPS were diluted in RPMI/H. PMN 
agonists, 20 µM IL-8, 100 ng/ml GM-CFS, 1 µM fMLP, 1 µg/ml PMA, 100 ng/ml 
LPS, or heat-killed LAC (107 cfu), were added to human PMNs (1 x 106) 
suspended in RPMI/H containing 4 µmol of EtBr. Samples were incubated for 30 
min at 37 °C. LPS was sonicated at a frequency of 40 kHz in ice water for 15 min 
before use (Branson 2200, Danbury, CT). The PMNs were then incubated with 1 
nM PVL (LukF-PV and LukS-PV) for the indicated times. EtBr uptake was 
assessed by flow cytometry (FACSCalibur).  
PMN lysis was determined by lactate dehydrogenase release (LDH) using 
the Cytotoxicity Detection Kit (Roche Applied Sciences, Pleasanton, CA) as 
previously described (7,29).  Human PMNs (100 µl, 1 x 106) were combined with 
1 nM, 2 nM, or 5 nM active PVL or iPVL in a 96-well plate (Costar, Corning, NY) 
and incubated at 37 ˚C for 3 h (total 200 µl/well). Plates were centrifuged at 1600 
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rpm for 7 min at 4 ˚C and 100 µl aliquots of each well were transferred to a new 
96-well plate. Percent LDH release was measured and analyzed as instructed by 
the manufacturer.  
 
3.3.5 PMN proinflammatory assays. 
The release of superoxide (O2-) was measured as previously described by 
DeLeo et al. (30) with modifications. PMNs (1 x 107/ml) were incubated at 37 ˚C 
for 30 min with fMLP, LPS, IL-8, GM-CSF, active PVL (LukF-PV and LukS-PV), 
heat-inactivated PVL (iPVL), or PVL subunits separately at concentrations 
described above (priming). Each agonist (1 µM fMLP, 20 µM IL-8, 100 ng/ml GM-
CSF, or 1 nM PVL final concentration) was aliquoted into wells of a 96-well 
microtiter plate before the addition of primed PMNs (1 x 106). LPS is a known 
PMN priming agent (31) and was a positive control for PMN priming. Unprimed 
PMNs were combined with 1 µg/ml PMA as a positive control for release of O2-. 
All wells contained ferricytochrome c (cyt c, Sigma Aldrich) at a final 
concentration of 100 µM. All assays were performed in triplicate ± 40 µg/ml 
superoxide dismutase (SOD, Sigma Aldrich). O2- production was determined by 
measuring the SOD-inhibitable reduction of cyt c at 550 nm for 20 min by using a 
microplate spectrophotometer (Synergy MX, Bio Tek, Winooski, VT) as described 
(30). Superoxide production was determined using the molar coefficient for cyt c 
(32) as described. 
Surface expression of CD11b was determined after PMNs (1 x 106) were 
exposed to 1 nM PVL for 0, 15, and 30 min at 37 ˚C. After exposure to PVL, cells 
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were washed twice with Stain Buffer (BD Biosciences) and incubated on ice for 
60 min with a 1:6 dilution of phycoerythrin (PE)-conjugated anti-human CD11b 
primary antibody or PE-labeled mouse IgG1 isotype control (BD Biosciences). 
PMNs were washed 3 times with Stain Buffer and analyzed by flow cytometry 
(FACSCalibur). 
Identification of molecules released from human PMNs following 
incubation with PVL was performed by Rules Based Medicine (RBM, Austin, TX). 
In brief, human PMNs from 4 different blood donors (1 x 107) were incubated ± 1 
nM PVL at 37 ˚C for 4 h. Cell suspensions were centrifuged at 1800 rpm for 10 
min at 4 ˚C. Supernatants were analyzed by Rules Based Medicine (HumanMAP 
v. 1.6) as described (http://www.rulesbasedmedicine.com/productsservices/ 
human-maps.aspx).  
 
3.3.6 PMN apoptosis assays. 
PMNs were exposed to 1 nM PVL or individual PVL subunits (LukF-PV or 
LukS-PV) as described above. Apoptosis was determined using published 
methods (33,34). PMNs (1 x 104) were analyzed using the Cytospin Octospot 
system (Thermo Scientific Shandon, Waltham, MA) as described by the 
manufacturer. PMNs were stained with Wright-Giemsa (Sigma Aldrich) and 
condensed nuclei were visualized by light microscopy (Zeiss, Axioskop 2 plus, 
Thornwood, NY) at x100 magnification. A total of 250 cells were scored from 5 
fields of view for each sample. Images were acquired with an AxioCam digital 
camera (Zeiss). Alternatively, PMN apoptosis was assessed using a modified 
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TUNEL assay (Apo-BRDU Apoptosis Detection Kit, BD Biosciences) as 
described by Kobayashi et al. (27). 
 
3.3.7 PMN microarray analysis. 
           PMNs (1 x 107) in RPMI/H were cultured with 1 nM PVL or iPVL at 37 ˚C 
for 30, 60, or 180 min. At each indicated time point, PMNs were lysed with RLT 
buffer and RNA was purified and used to generate ≥ 12 µg of biotin-labeled 
cRNA target as previously described (27,34).  Samples from 3 different PMN 
donors were analyzed on HU133+2 GeneChips (Affymetrix, Santa Clara, CA). 
cRNA labeling, GeneChip hybridization, and scanning were completed according 
to GeneChip manufacturer protocols (http://media.affymetrix.com/support/ 
downloads/manuals/expression_analysis _technical_manual.pdf). Gene chip 
hybridization and subsequent scanning was performed by the NIAID-RML 
Genomics Core Unit at Rocky Mountain Laboratories (Hamilton, MT). Vehicle 
controls were analyzed to determine levels of background signal for each donor 
at every time point.  
           Microarray data was normalized using GeneChip Operating Software 
(GCOS v1.4). At each time point, PMNs cultured with active PVL were compared 
directly to those treated with iPVL and a principal component analysis (PCA) was 
performed using Partek Genomics Suite (Partek, Inc., St. Louis, MO). Genes 
were defined as differentially expressed if they were significantly different from 
the iPVL control (p ≤ 0.01, two-way analysis of variance, ANOVA), changed two-
fold in expression, and had signal levels above background. The Venn diagram 
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was generated using the iVenn program (NIAID Genomics Core Unit, RML, 
Hamilton, MT). Analysis of signal transduction pathways was performed with 
Ingenuity Pathway Analysis (IPA, Redwood City, CA).    
  
3.3.8 Statistical analysis. 
Rules Based Medicine data were evaluated using a Student’s t-test 
(Microsoft Office Excel 2007, Microsoft Corporation, Redmond, WA). PMN 
apoptosis data in Fig. 11 were assessed using a Student’s t-test (GraphPad 
Prism 5, GraphPad Software, Inc., San Diego, California). PMN pore formation 
data in Fig. 12 were compared using a one-way analysis of variance (ANOVA) 
and Dunnett’s posttest to correct for multiple comparisons (GraphPad Prism 5).  
 
3.4 Results 
3.4.1 Sublytic concentrations of PVL alter human neutrophil function.  
            We first determined the concentration at which PVL from USA300 strain 
LAC culture supernatants causes formation of plasma membrane pores but 
limited cytolysis (Fig. 11A).  By 30 min, greater than 90% of PMNs were EtBr-
positive at each of the PVL concentrations tested (pore formation was 93%, 98%, 
and 99% for 1 nM, 2 nM, and 5 nM PVL, respectively). PMN lysis was measured 
by release of lactate dehydrogenase using conditions identical to the pore-
formation assays, but incubation time was extended to 3 h (Fig. 11C). Despite 
high levels of pore formation with 1 and 2 nM PVL, subsequent cell lysis was 
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limited (9 ± 3% and 15 ± 11%, respectively). We note that cell lysis increased 
significantly between 2 nM and 5 nM (e.g., lysis was 52 ± 6% using 5 nM PVL). 
Heat-inactivated PVL (iPVL) caused no pore formation and had zero cytolytic 
capacity (Fig. 11A and C). 
Figure 11. Determining concentrations of purified PVL that remain 
sublytic. A) Pore formation. PMNs (1 X 106) were incubated with 1 nM, 2 nM, 
or 5 nM native or denatured PVL for 30 min and plasma membrane 
permeability was evaluated using an ethidium bromide (EtBr) uptake assay. 
Each symbol represents a separate experiment and black bars indicate the 
mean. iPVL, heat-inactivated PVL. B) PVL purified from USA300. FPLC-
purified PVL subunits (LukF-PV = F and LukS-PV = S) from USA300ΔhlgABC 
culture supernatants were analyzed by SDS-PAGE. The gel was stained with 
GelCode Blue Stain. C) PMN lysis. PMNs (1 X 106) were incubated with 1 nM, 
2 nM, or 5 nM native or denatured PVL for 3 h. Lysis was determined by a 
standard assay that measures release of lactate dehydrogenase (LDH).  Bars 
indicate the mean ± SEM of three donors.  
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We next performed a series of experiments to determine whether sublytic 
concentrations of PVL altered human PMN function as reported previously. 
Indeed, 1 nM PVL accelerated neutrophil apoptosis (Fig. 12A and B), 
observations consistent with previous work by Genestier et al. (26). These 
findings were specific for active PVL, since neither PVL subunit alone (LukF-PV 
or LukS-PV) altered neutrophil survival. 
          In accordance with previous studies (22), 1 nM PVL caused enhanced 
release of superoxide (O2-) after stimulation with fMLP (Fig. 13A) and 
Figure 12. PVL accelerates 
PMN apoptosis. A) Nuclear 
condensation. PMNs (1 X 106) 
were cultured with 1 nM PVL 
(LukF-PV + LukS-PV) and 
condensed nuclei were scored by 
microscopy. Inset, representative 
images of PMNs alone (Ctrl) and 
PMNs exposed to 1 nM PVL 
(+PVL) at 3h. The black arrow 
indicates a representative 
condensed nucleus. B) TUNEL 
Assay. TUNEL-positive PMNs 
were determined by flow 
cytometry using the same culture 
conditions as in panel A. Results 
from panel A and B are the mean 
± SEM of four PMN donors.  
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upregulation of CD11b at the plasma membrane (Fig. 13B and C). As with other 
priming agents (31, 35), PVL failed to elicit O2- production when used subsequent  
to fMLP (Fig. 13A). Collectively, these findings are consistent with the ability of 
PVL to function as a neutrophil priming agent.  
 
3.4.2 Proinflammatory molecules alter neutrophil susceptibility to PVL.  
Figure 13. PVL alters human 
neutrophil function. A) 
Priming for enhanced release 
of O2-. PMNs (1 X 106) were 
incubated with 1 nM PVL 
(LukF-PV + LukS-PV), 1 nM 
heat-denatured PVL (iPVL), or 
1 nM of individual PVL 
subunits (LukF-PV or LukS-
PV) for 30 min as indicated. 
PMNs were incubated for 30 
min and then activated with 1 
µM fMLP. Superoxide 
production was measured 
using standard assay for 
reduction of ferricytochrome c.  
Results represent the mean of 
four separate experiments. B) 
Surface expression of CD11b. 
PMNs (1 X 106) were 
incubated with 1 nM PVL (+ 
PVL) or buffer alone (- PVL) 
and surface expression of 
CD11b was measured by flow 
cytometry. C) Quantification of 
CD11b surface expression. 
Bars indicate the mean 
fluorescence (FL2) of four 
separate experiments.  
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          Inasmuch as proinflammatory factors typically prime PMNs for enhanced 
function, which includes reorganization/redistribution of molecules at the plasma  
membrane, proinflammatory stimuli could conceivably influence the outcome of 
the PVL-PMN interaction. To test this hypothesis, we expanded our in vitro 
assays to include stimulation of human PMNs with multiple proinflammatory 
factors and evaluated PVL-mediated pore formation (Fig. 14A and B). Priming 
with fMLP or activation with PMA caused a significant decrease in the ability of 
PVL to form pores in the PMN plasma membrane (e.g., 48 ± 10% of the fMLP 
primed cells were EtBr-positive following exposure to PVL versus 81 ± 12% EtBr-
positive cells following exposure to PVL alone) (Fig. 14A). By comparison, 
neither LPS nor heat-killed USA300 (HK LAC) altered the ability of PVL to cause 
formation of membrane pores. On the other hand, priming of PMNs with IL-8 or 
GM-CSF caused a transient but significant increase in pore formation  
(e.g., by 15 min 83 ± 5% of the PMNs were EtBr-positive after exposure to IL-8 
compared with 65 ± 6% of those incubated with PVL alone, p ≤ 0.01) (Fig. 14B). 
These data indicate that remodeling of the neutrophil plasma membrane 
following exposure to specific proinflammatory agonists alters the ability of PVL 
to interact with PMNs. One possible explanation for these results is that PVL 
binds to a PMN receptor whose surface expression changes following exposure 
to specific agonists. 
          We next determined if PVL induces O2- release from PMNs primed with IL-
8 or GM-CSF (Fig. 15). IL-8 and GM-CSF primed neutrophils for enhanced fMLP-
mediated O2- release (positive control, open circles) as described previously  
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Figure 14. Proinflammatory molecules alter neutrophil 
susceptibility to PVL. A) Pore formation. PMNs (1 X 106) were 
cultured with 100 ng/mL LPS, 1 µM fMLP, 20 µM interleukin-8 (IL-8), 1 
µg/mL phorbol-12-myristate-13-acetate (PMA), 100 ng/mL granulocyte-
macrophage colony-stimulating factor (GM-CSF), or heat-killed USA300 
S. aureus strain (HK LAC) (LAC, 1:10 bacteria to PMN ratio) for 30 min 
in Hepes-buffered RPMI 1640. PMNs were then incubated with 1 nM 
PVL and subsequently assayed for EtBr uptake. Each symbol 
represents a separate experiment. Colors indicate separate PMN 
culture conditions as indicated. Red bars indicate mean percent EtBr-
positive PMNs.  B) Temporal increase in PMN susceptibility to PVL 
following exposure to IL-8 or GM-CSF. ***, p ≤ 0.001 vs. ▲ and **, p ≤ 
0.01 vs. ▲ using a one-way analysis of variance (ANOVA) with a 
Dunnett’s posttest. Ctrl, PMNs + 1 nM PVL (positive control).  
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(36-38). PVL caused O2- release from IL-8 and GM-CSF primed neutrophils, 
albeit 3-4 times less than that caused by secondary stimulation with 
fMLP (open triangles). Collectively, these data indicate that the ability of PVL to 
interact with human neutrophils is dictated by the activation state of the cell, and 
thus the interaction is specific to some degree. 
 
3.4.3 PVL induces global changes in PMN gene expression. 
          To gain insight into the molecular basis of PVL-mediated neutrophil 
priming, we measured global changes in PMN gene expression following 
exposure to 1 nM PVL (Fig. 16 and 17). The number of differentially expressed 
genes increased in a time-dependent manner (there were 397 differentially-
Figure 15. Effects of PVL on PMN superoxide (O2-) release. O2-
production was determined by reduction of ferricytochrome c as 
described in Materials and Methods. Left panel, PMNs were primed with 
PVL and then stimulated with IL-8 (blue open circles) or GM-CSF (red 
open circles). Alternatively, PMNs were primed with IL-8 or GM-CSF and 
then stimulated with PVL (open triangles) or fMLP (closed triangles). 
Right panel, assays performed without a secondary stimulus. 
81 
 
expressed genes at 30 min, 1074 differentially-expressed genes at 60 min, and 
2850 differentially-expressed genes at 180 min) (Fig. 16). Differentially- 
 
expressed genes were categorized into biological pathways or grouped 
according to function using IPA software (Fig. 17). Only 9 signal transduction 
pathways were significantly represented by differentially-expressed genes at 30 
min (Fig. 17). However, 30 and 114 signal transduction pathways were 
significantly represented by differentially-expressed genes at 60 min and 180  
Figure 16. PVL causes global changes in PMN gene 
expression. PMNs (1 X 107) were cultured with 1 nM native or 
heat-inactivated PVL and changes in transcript levels between the 
two conditions were measured using Affymetrix HU133+2 
GeneChips as described in Materials and Methods. Venn diagram 
depicting the total number of differentially expressed genes at each 
time point.   
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min, respectively (not shown). In general, proinflammatory pathways such as 
CD40 and epidermal growth factor (EGF) signaling are significantly represented 
early following the PVL-PMN interaction (30 min). By comparison, cell fate 
Figure 17. Signal transduction pathways represented by 
differentially-expressed genes. Pathways or processes were 
identified using Ingenuity Pathway Analysis as described in Materials 
and Methods. The p-value is the measure of the likelihood that the 
association of differentially expressed genes with a given pathway is 
due to random chance. 
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pathways such as death receptor signaling and myc-mediated apoptosis 
signaling are more highly represented in PMNs by 60 and 180 min after exposure 
to PVL (Fig. 17). 
 
3.4.4 Expression of PMN genes encoding major transcription regulators is 
increased following exposure to PVL.  
Genes encoding proteins known to mediate the inflammatory response, 
such as STAT3, SOCS3, JUNB, FOS, JUN, FOSB, FOSL1, and TANK were 
upregulated 30 or 60 min after PMN exposure to 1 nM PVL (Fig. 18). Expression 
of SOCS3 is regulated by the transcription factor STAT3. Therefore, upregulation 
of SOCS3 is consistent with activation of STAT3 (39,40).  JUNB, FOS, JUN, 
FOSB, and FOSL1 encode proteins that dimerize and form the AP-1 transcription 
factor, which is known to associate with NF-kappaB as a result of signal 
transduction through proinflammatory pathways (41). TANK is a downstream 
kinase involved in proinflammatory signal pathways that regulate NF-kappaB 
activation (42,43). Genes involved in NF-kappaB signal transduction were 
differentially expressed 180 min after exposure of PMNs to PVL. For example, 
the gene encoding NF-kappaB inhibitor delta (IkBδ or NFKBID) was upregulated 
and MAP3K3 (MEKK3) was downregulated, a finding consistent with a decrease 
in IKKβ activation. Increased expression of MALT1, BCL10, and BCL3 by PMNs 
after exposure to PVL suggests NF-kappaB is activated via nonclassical 
pathways (42-46).  
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Figure 18. PVL alters expression of genes encoding proteins 
involved in inflammation and cell fate. Transcript levels were measured 
as described in Materials and Methods.  Colors represent the mean 
increase or decrease (fold-change) in gene expression in PMNs treated 
with native PVL relative to those treated with heat-denatured PVL (iPVL).  
Results are the mean of three separate experiments or donors. 
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3.4.5 Priming of PMNs with PVL alters expression of transcripts encoding surface 
receptors and proinflammatory molecules. 
Several PMN proinflammatory mediators were upregulated 180 min after 
exposure to PVL (e.g., FCAR, encoding CD89; and CR1, which encodes CD35).  
CD89 is an IgA receptor expressed on phagocytic cells and can promote 
phagocytosis (47). CD35 binds the serum complement components C3b and 
C4b at the microbial surface (48,49), thereby facilitating phagocytosis and 
neutrophil activation through complement receptor activation (50).  Genes 
encoding chemokines GROα (CXCL1), GROβ (CXCL2), and the cytokine 
oncostatin M (OSM) were upregulated after exposure to PVL. GRO proteins 
(members of the interleukin-8 superfamily) are expressed and secreted by 
several cell types including neutrophils (51-54). Oncostatin M, a member of the 
interleukin-6 family, is stored by mature PMNs as an active protein and released 
following priming or activation. However, de novo synthesis of OSM is known to 
occur under certain conditions (55) and previous studies have shown transient 
upregulation of the transcript after phagocytosis (56,57).   
Upregulation of PMN proinflammatory surface receptors and molecules 
after PMN exposure to PVL (described above) is comparable to the increased 
expression of proinflammatory molecules following priming with LPS and GM-
CSF (34,58-63). In contrast to other agonists, exposure of neutrophils to PVL 
also culminated in relatively early downregulation of genes encoding other 
surface receptors and cytokines involved in the inflammatory response (Fig. 18). 
For example, IL5RA, IL1R1, IL1A, CCL23 (MIP-3), TNFRSF12A, TNFRSF10A, 
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and TNF (encoding tumor necrosis factor alpha, TNFα) were repressed 60 min 
after exposure of human neutrophils to PVL. Control of the TNFα-mediated 
immune response is important for the resolution of inflammation (64-66). 
Downregulation of transcripts encoding TNF receptors and TNFα at later time 
points (60 and 180 min) provides support to the idea that there is eventual 
moderation of the proinflammatory response induced by PVL, a phenomenon 
consistent with induction of PMN apoptosis (Fig. 12A and B).   
Expression of DIABLO (SMAC), CYCS, and APAF1 was increased after 
incubation with PVL, findings compatible with activation of caspase 9. This 
observation is consistent with previous findings reporting activation (proteolytic 
cleavage) of caspase 9 and caspase 3 following exposure of PMNs to 
recombinant PVL (26). Furthermore, expression of the anti-apoptotic genes XIAP 
and CFLAR (c-FLIP) was repressed (67,68). Taken together, these data suggest 
that exposure of human PMNs to PVL activated proinflammatory signal 
transduction pathways, an event followed by differential expression of genes 
involved in cell fate. 
 
3.4.6 Multiple proinflammatory molecules are released from neutrophils following 
PVL priming. 
          Inasmuch as PVL primes neutrophils for enhanced function and caused 
upregulation of transcripts involved in the proinflammatory response, we next 
measured release of proinflammatory molecules from PMNs following exposure  
to sublytic concentrations of PVL (Table 1). PVL caused release of multiple 
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Table 1. PVL-mediated release of proinflammatory molecules. Supernatants 
were analyzed by RBM using microsphere-based immuno-multiplexing. Asterisks 
indicate molecules whose concentrations remained below or at the lower limit of 
detection (LOD) and the LODs were used to calculate a conservative p value.  
 
 
Protein 
Control (ng/mL) 
(mean ± S.D.) 
(n = 4) 
+1 nM PVL (ng/mL) 
(mean ± S.D.) 
(n = 4) 
P value
Ferritin 0.5200 ± 0.1226 19.50 ± 2.887 0.0009 
Vascular endothelial growth factor 0.0198 ± 0.0128 0.5740 ± 0.1740 0.007 
Interleukin-1 receptor antagonist *0.0067 ± 0.0025 0.0408 ± 0.0091 0.009 
Tumor necrosis factor receptor 2 0.1860 ± 0.1132 0.4380 ± 0.1282 0.01 
Insulin-like growth factor-1 6.630 ± 0.9500 10.40 ± 1.451 0.01 
Prostatic acid phosphatase 0.0500 ± 0.0083 0.4200 ± 0.1547 0.02 
Myeloperoxidase 342.3 ± 98.10 9003 ± 3642 0.02 
Growth hormone *0.0200 ± 0.000 0.0500 ± 0.0163 0.02 
Serum amyloid P component 2.500 ± 2.400 4.000 ± 2.200 0.02 
CD40 *0.0044 ± 0.000 0.0120 ± 0.0034 0.03 
Plasminogen activator inhibitor 1 0.0500 ± 0.0123 0.0800 ± 0.0149 0.03 
EN-RAGE 16.75 ± 10.31 143.8 ± 68.04 0.04 
Interleukin-8 0.0061 ± 0.0028 0.0334 ± 0.0166 0.05 
Cancer antigen 19-9 (µU/mL) *320.0 ± 0.000 845.0 ± 349.9 0.06 
Tissue inhibitor of metalloproteinases 1 0.2700 ± 0.1857 1.083 ± 0.7054 0.06 
Carcinoembryonic antigen *0.0400 ± 0.0040 0.1700 ± 0.0851 0.06 
Factor VII *0.1100 ± 0.000 0.4000 ± 0.2335 0.09 
Adipoliporotein (a) 23.00 ± 8.100 39.00 ± 14.50 0.1 
Interleukin-6 *0.0004 ± 0.000 0.0011 ± 0.0007 0.1 
Tyroid stimulating hormone (µIU/mL) *0.0041 ± 0.000 0.0080 ± 0.0041 0.2 
Interleukin-1 beta *0.0002 ± 0.000 0.0048 ± 0.0062 0.2 
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proinflammatory mediators, including IL-8, IL-6, VEGF, and myeloperoxidase 
(MPO), from human neutrophils. In addition, we observed significant 
accumulation of tumor necrosis factor receptor 2 (TNFR2) and IL-1 receptor 
antagonist (IL-1RA) in RPMI 1640 culture media after incubation of PMNs with 
PVL. Neutrophils are known to shed TNFR2 following stimulation with fMLP and 
GM-CSF, thereby decreasing the subsequent PMN response to TNFα (64). 
PMNs stimulated in vitro with LPS or GM-CSF released of IL-1β and IL-1RA; 
however, concentrations of IL-1RA are significantly higher than those of IL-1β 
(66). Consistent with these previous studies, 1 nM PVL caused accumulation of 
10 times more IL-1RA than IL-1β in PMN culture media (there was 0.0408 ± 
0.0091 ng/ml IL-1RA and 0.0048 ± 0.0062 ng/ml IL-1β in culture media after 
exposure to PVL).   
 
3.5 Discussion 
Recent multinational phase III clinical trials indicate that presence of pvl 
genes is not the primary determinant of outcome in patients with MRSA skin and 
soft tissue infection. In fact, individuals with PVL-positive infections were more 
likely to be cured (69,70). It is also noteworthy that the concentration of PVL 
achieved during S. aureus infection in vivo may be insufficient to cause PMN 
lysis (71,72), findings that bring into question the role of PVL as a cytolytic toxin. 
Antibodies against PVL are present in individuals with previous confirmed S. 
aureus infections caused by either PVL-positive or PVL-negative strains (73,74). 
These observations suggest that some of the antibodies were originally elicited 
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by two-component toxins other than PVL, but the antibodies cross-react with 
PVL.  Recurrent infections with PVL-positive S. aureus strains occur in patients 
that have anti-PVL antibodies, findings that suggest PVL has little or no role in 
establishment of infection (75). Furthermore, a previous study demonstrated that 
administration of anti-PVL antibodies prior to USA300 or USA400 infection (pvl-
positive) hindered clearance of infection (76). This observation seems at variance 
with the presumed role of during infection (i.e., cytolytic toxin that enhances 
virulence), but is consistent with the ability of the molecule to function as a 
neutrophil priming agent. 
The cytolytic properties of PVL are well known from extensive work in 
vitro. However, there is paucity of evidence to indicate that the primary function 
of PVL in vivo is cytolysis of host leukocytes. Furthermore, in vitro studies 
indicate S. aureus is rapidly ingested by neutrophils and that these host 
phagocytes undergo rapid lysis independent of PVL (7,29). Thus, the role played 
by PVL during infection remains unclear. 
Sublytic concentrations of PVL are known to prime neutrophils for 
enhanced release of O2-, and cause release of IL-8, IL-6 and PMN granule 
contents, such as MPO and lysozyme (18-21). Previous studies demonstrated 
that granule exocytosis occurs in intact PMNs following incubation with PVL (77). 
Furthermore, Konig et al. reported that inhibition of protein tyrosine kinases 
decreases release of IL-8 from PMNs exposed to sublytic levels of PVL (20). 
Consistent with these previous studies, we found that neutrophils incubated with 
1 nM PVL remained intact, as there was little or no release of LDH using these 
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assay conditions (Fig. 11C).  Taken together, these data provide strong support 
to the idea that PVL-mediated release of neutrophil proinflammatory molecules 
was caused by activation of signal transduction pathways rather than cytolysis.  
In accordance with previous work, PVL had proinflammatory effects on 
human neutrophils, including priming for enhanced release of O2-, upregulation of 
CD11b, and secretion of TNFR2, IL-1RA, and IL-1β. The proinflammatory 
response elicited by PVL is similar to that caused by inflammatory cytokines or 
bacterial components such as GM-CSF and LPS (34,62,78). One major 
difference is that exposure of PMNs to PVL caused release of MPO, a protein 
sequestered in azurophilic granules (15) (Table 1). Exocytosis of azurophilic 
granules is not typical of priming with GM-CSF (79), IL-8 (80), or LPS (81). 
Rather, this phenomenon typically indicates full activation of neutrophils. PVL 
also accelerated PMN apoptosis at a concentration that elicits a proinflammatory 
response (Fig. 12A and B), which is at variance with the ability of other priming 
agents to extend PMN survival in vitro. Our finding that genes encoding 
apoptosome proteins, DIABLO (SMAC), CYCS, and APAF1, were upregulated 
after exposure to PVL suggests that the caspase 9/3 pathway participates in 
PVL-mediated apoptosis (Fig. 18). Previous studies have linked induction of 
PMN apoptosis to inactivation of the NF-kappaB pathway (82,83). Differential 
expression of PMN genes directly transcribed by NF-kappaB subunits (ICAM1, 
TNF) and those encoding proteins that in regulate NF-kappaB activity (BCL3, 
BCL10, and MALT1) suggest this pathway is activated following exposure to 
PVL.  
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PMNs are exposed to a multitude of proinflammatory molecules during 
infection in vivo and different combinations of stimuli are known to elicit different 
PMN responses (84). The application of this idea to PVL-positive S. aureus 
infections is perhaps reflected by our finding that fMLP, GM-CSF, and IL-8 alter 
the ability of PVL to interact with PMNs (Fig. 14A and B). Data in this study 
suggest that sublytic concentrations of PVL prime PMNs for enhanced 
microbicidal capacity. This notion is supported by Yoong et al. (76), in which anti-
PVL rabbit sera inhibited PMN killing of several PVL-positive S. aureus strains in 
vitro. By comparison, killing of isogenic pvl mutants by PMNs was similar in the 
presence or absence of anti-PVL antibody (76). Collectively, these observations 
suggest that PVL can enhance rather than hinder the host innate immune 
response to S. aureus infection. Nonetheless, the ability of PVL to alter PMN 
bactericidal activity in vivo merits further investigation. Elucidation of activated 
secondary messenger proteins following such stimulation with PVL may provide 
new insight into the ability of specific agonists to elicit differential responses from 
human neutrophils.  
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CHAPTER FOUR 
SUMMARY 
 
4.1 Significance of the work presented in this dissertation 
 
4.1.1 S. aureus virulence and cytolytic toxins. 
The success of S. aureus as a human and animal pathogen is largely 
associated with its ability to produce a multitude of toxins.  For example, S. 
aureus produces several cytolytic molecules with well-characterized in vitro 
activity that contribute to virulence. The host range is varied among S. aureus 
toxins and some, such as the alpha-type phenol soluble modulins (PSMs), have 
the ability to target a broad range of host cells.  PSMs are a group of relatively 
short amphipathic peptides that are encoded in the S. aureus core genome (1). 
Importantly, PSMs are one of the few molecules known to contribute to the 
enhanced virulence phenotype of CA-MRSA strains such as USA300 (1). Alpha-
hemolysin (α-hemolysin, Hla) is an exotoxin that is encoded in the core genome 
of virtually all S. aureus strains. Hla is secreted as a soluble monomer, forms a 
heptameric pore in the plasma membrane of target cells (2), and has cytolytic 
activity toward epithelial cells, erythrocytes, monocytes, lymphocytes, fibroblasts, 
and platelets (3,4). In addition, S. aureus produces several bicomponent pore-
forming toxins (PFTs) that are tropic for leukocytes such as macrophages, 
monocytes, and neutrophils. The pore-forming activity of this group of related 
leukotoxins requires two components, a LukS subunit and a LukF subunit.  
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Alternating LukF and LukS components form a pore in the plasma membrane of 
leukocytes. PFTs that are expressed by S. aureus include gamma-hemolysin (γ-
hemolysin, Hlg), LukG-LukH (LukGH), LukD-LukE (LukDE), and PVL (comprised 
of LukS-PV and LukF-PV) (4-6). Similar to the hla operon, genes that encode Hlg 
(hlgABC) and LukGH (lukG/H) are essentially ubiquitous in clinical isolates of S. 
aureus (6,7). Two combinations of Hlg subunits, HlgA-HlgB or HlgA-HlgC, 
aggregate on the surface of erythrocytes and leukocytes and cause lysis of these 
cells (8-10). LukGH is freely secreted and bound to the surface of S. aureus. This 
toxin was recently shown to cause lysis of neutrophils (6). LukDE is encoded in 
the genome of ~30% of clinical isolates (11); however, the lukDE operon is 
harbored by many prominent HA-MRSA and CA-MRSA strains (11-13). This 
bicomponent PFT is weakly leukotoxic (11). PVL lyses neutrophils and other 
myeloid cells in vitro and many CA-MRSA strains harbor genes that encode PVL 
(lukS/F-PV) (12,14,15). However, only 2-5% of all clinical S. aureus isolates 
contain lukS/F-PV (7,16,17).  
There is striking redundancy in cytolytic activity among the S. aureus 
leukotoxins. Presumably, destruction of neutrophils and other leukocytes confers 
an increased ability of S. aureus  to evade the host innate immune response. It 
remains a mystery why S. aureus in general produce so many molecules that 
potentially have a similar role in virulence. S. aureus causes a wide range of 
infections with varied degrees of severity (16,18-20). Perhaps such redundancy 
in toxin function is advantageous for the pathogen, as it might enable S. aureus 
to colonize and/or cause infection in several niches in the human host. For 
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example, it is known that expression of PVL and Hlg by S. aureus is highly 
influenced by in vitro culture conditions (21,22). These findings underscore the 
notion that specific conditions in vivo likely impact expression of cytolytic toxins 
and could thereby influence the outcome of infection. In addition, the combination 
of PVL and LukGH causes lysis of human neutrophils that is greater than that 
caused by either toxin alone, suggesting that specific leukotoxin combinations 
are additive or synergistic (6). The concerted action of both toxins may further 
enhance the success of S. aureus as a human pathogen.  
 PVL-positive strains compromise a small fraction of all S. aureus clinical 
isolates, and correspondingly, there is an association of these strains with a 
relatively small subset of skin infections (e.g. furuncles and carbuncles) and 
necrotizing pneumonia with antecedent influenza (14,19,23-25). It is therefore 
possible that PVL confers some advantage to S. aureus under specific conditions 
or niches in vivo. The acquisition of lukS/F-PV requires horizontal transfer of a 
prophage (26,27). Therefore, acquisition of lukS/F-PV is either uniquely not 
important (with the possible exception of particular S. aureus infections) and/or 
the genetic background of specific S. aureus lineages may be less compatible 
with prophage insertion into the genome (restriction system), thus limiting the 
number of PVL-positive strains. Inasmuch as the vast majority of S. aureus 
clinical isolates encode Hla, PSMs, and other molecules that contribute to 
infection, PVL is clearly not required to cause disease. Additionally, epidemic 
PVL-positive CA-MRSA lineages remain fairly specific in geographic distribution 
(28), which suggests that factors other than PVL determine global segregation of 
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pathogenic strains. S. aureus, including PVL-positive strains, presumably have 
had the opportunity to disseminate to any global region, given the high levels of 
international travel. The limited prominence of PVL-positive clinical isolates 
overall supports the notion that PVL may have a role in specific types of infection 
or function only in the presence of particular host factors.  
4.1.2 Does PVL contribute to the lysis of human neutrophils? 
Historic studies clearly demonstrated that purified native PVL is cytolytic 
toward rabbit and human neutrophils (29-31). In addition, PVL-mediated cytolysis 
is concentration-dependent and concentrations of PVL less than 2 nM cause 
formation of membrane pores but little or no cytolysis (21,30,31). Genestier et al. 
(32) demonstrated that cytolysis of human neutrophils occurs following incubaton 
with 200 nM of recombinant PVL (rPVL). In contrast, exposure of PMNs to a 
sublytic level of rPVL (5 nM) accelerates neutrophil apoptosis rather than causing 
necrosis (lysis). Similarly, a study by Loffler et al. (17) confirmed the finding that a 
low concentration of rPVL (80 ng/ml or ~1.1 nM) accelerates neutrophil 
apoptosis.  However, these authors also reported that 80 ng/ml causes a 90% 
decrease in intact cells (reported as % of intact cells) at 20 min, a finding 
consistent with a high degree of PMN lysis under those assay conditions.  The 
apparent discrepancy in these reports is likely explained by differences in 
methodology used to determine cell lysis.  For example, Genestier et al. (32) 
measured cell lysis by microscopy, whereas Loffler et al. (17) used a less direct 
method (uptake of propidium iodide) that determines pore formation and not 
necessarily cell lysis.  There was a similar discrepancy between Loffler et al. (17) 
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and Voyich et al. (33). These studies examined the contribution of PVL to PMN 
lysis in vitro by use of S. aureus culture supernatants. Voyich et al. (33) found 
that culture supernatants derived from USA300 and USA400 wild type (WT) or 
isogenic lukS/F-PV deletion (Δpvl) strains caused comparable levels of PMN lysis 
(33). By contrast, Loffler et al. (17) reported that culture supernatants from 
USA300Δpvl caused decreased neutrophil lysis compared to those from the 
corresponding WT strain. By inspection, the disparities between these data 
appear to be the result of two factors: 1) utilization of different methods to assess 
PMN lysis, and 2) use of culture supernatants from different in vitro growth 
media. Loffler et al. (17) determined levels of cytolysis by measuring uptake of 
propidium iodide (PI) while Voyich et al. (33) measured extracellular release of 
lactate dehydrogenase (LDH). Although uptake of PI was used as an indicator of 
neutrophil lysis, such an approach operates under the assumption that PVL-
mediated pore formation correlates directly with cytolysis. However, results 
presented in Chapter 2 of this dissertation demonstrate that there is not a direct 
correlation between EtBr uptake (pore formation) and LDH release by human 
PMNs. Therefore, Loffler et al. (17) measured cell membrane permeability but 
not necessarily necrosis.  
Some of the incongruity in these studies in vitro is also likely attributed to the 
use of supernatants from different culture media. This idea is supported by 
results presented in Chapter 2 indicating that production of PVL is highly 
influenced by different culture conditions in vitro. Growth of PVL-positive strains 
in CCY, particularly USA300, is optimal for high production of PVL, whereas 
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growth in TSB or 100% human serum is not. Accordingly, the variability in 
quantities of PVL present in culture supernatants from different media in vitro 
partly explains why there are disparities in the literature as exemplified by Voyich 
et al. (33) and Loffler et al. (17). Taken together, these data indicate that 
differential expression of PVL in vitro alters the contribution of PVL to pore 
formation and cytolytic activity of culture supernatants (Chapter 2). PVL-positive 
culture supernatants from S. aureus growth media that more closely represent in 
vivo growth conditions (e.g., human serum) support little or no accumulation of 
PVL. Furthermore, culture supernatants that have limited PVL-mediated cytolytic 
activity (Chapter 2, Fig. 8 TSB) contain quantities of PVL comparable to that in 
material recovered from human S. aureus infections (34,35). These findings 
indicate that in vitro assays with culture supernatants are of limited utility for 
estimating the contribution of PVL to S. aureus virulence. Consistent with this 
idea, there is no correlation between levels of PVL produced in vitro by clinical 
isolates and disease severity (36). The observation that concentrations of PVL in 
vivo (34,35) are largely limited to those that cause pore formation but limited lysis 
in vitro (Chapter 2) challenges the widely accepted notion that the primary role of 
PVL during infection is to cause cytolysis of leukocytes.  
 
4.1.3 PVL as an immune modulatory agent. 
  Given that in vivo expression of PVL likely does not achieve a 
concentration necessary to cause significant neutrophil lysis, we examined the 
ability of sublytic concentrations of PVL to alter PMN function (Chapter 3). 
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Sublytic concentrations of PVL prime neutrophils for enhanced release of O2-, 
and induce extracellular release of IL-8, IL-6 and PMN granule contents (37-40). 
Previous studies indicate that there is optimal release of O2- from PVL-primed 
neutrophils following stimulation with fMLP (41,42, and confirmed in Chapter 3). 
However, the molecular basis for PVL-mediated priming of neutrophils is 
unknown. 
  Our results indicate that PVL elicits a proinflammatory response from 
human PMNs. One of the major goals of this dissertation (Chapter 3) was to 
characterize the molecular mechanism by which PVL primes neutrophils for 
enhanced response to a secondary agonist. Enhanced release of ROS from 
PMNs primed with PVL requires a specific order of events as indicated by O2- 
release assays (Fig. 13A and 15). Neutrophils primed with IL-8 or GM-CSF have 
increased susceptibility to PVL-mediated pore formation, whereas cells primed 
with fMLP or activated with PMA are resistant to pore formation (Fig. 14). These 
data suggest that the activation state of the human neutrophil determines the 
extent to which PVL is capable of causing pore formation and O2- release. 
Inasmuch as neutrophils interact with proinflammatory molecules such as IL-8 
during S. aureus infection, alterations in microbicidal activity under these 
conditions merits investigation. To further examine the molecular basis of PVL-
mediated priming, PMNs were exposed to PVL and the culture medium was 
analyzed for accumulation of molecules known to be involved in the 
proinflammatory response. We discovered that several notable proinflammatory 
agents were released by PMNs following exposure to PVL (Table 1), including 
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molecules previously reported to be released by PMNs under these conditions 
(37-40). Collectively, these data provide new insight into how PVL in vivo might 
alter the outcome of infection.  
  Microarray experiments with PVL-treated PMNs were performed to gain a 
broad understanding of the molecular mechanism of PVL-mediated neutrophil 
priming. The microarray data suggest that PMN exposure to PVL triggers 
activation of STAT3 and NF-kB signal transduction pathways. Both of these 
pathways are known to mediate the proinflammatory response in multiple cell 
types, including neutrophils. These data provide a basis for future studies to 
explore how PVL, as an immune modulatory agent, alters the host-S.aureus 
interaction.  
  Although our work reveals the potential of PVL as an immune-modulatory 
agent, such a function remains to be determined in vivo. Nonetheless, recent 
studies have shown that Hla, another S. aureus cytolytic toxin, has an immune 
modulatory function in vivo. Hla is essential for mortality in mouse models of 
pneumonia and the level of Hla expression correlates with severity of infection 
(43). Production of Hla during experimental S. aureus pneumonia in mice 
increases quantities of CXCL1, CXCL2, and TNFα present in lung tissue, which 
in turn recruits neutrophils to the lungs (44). This enhanced neutrophil 
recruitment ultimately results in severe lung tissue destruction and death.  It is 
well accepted that neutrophils can cause significant host tissue damage under 
conditions in which the inflammatory response is dysregulated and/or there is not 
timely removal of effete cells (45,46). Hla in vitro elicits release of 
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proinflammatory molecules such as IL-8, IL-1β and TNFα from monocytes and 
endothelial cells (47-49). These findings indicate that the role of S. aureus 
exotoxins in pathogenesis is not be solely based on cytolytic activity. Rather, the 
host inflammatory response elicited by secreted exotoxins is likely a major factor 
in determining the outcome of S. aureus infection. This notion is supported 
further by Bubeck Wardenburg et al. (50) who reported that protection against 
CA-MRSA pneumonia is associated with different cytokine profiles compared to 
unvaccinated controls. 
  In contrast to Hla, there is little in vivo evidence to suggest that PVL 
increases the severity of experimental CA-MRSA pneumonia (43,51), with the 
exception of a single study (52). Diep et al. (52) reported a moderate increase in 
mortality and lung inflammation following infection with a high bacterial inoculum. 
S. aureus necrotizing pneumonia is typically associated with S. aureus strains 
that contain genes encoding for PVL (14,23,25), and Diep et al. (52) 
demonstrated that purified PVL causes lung inflammation. A caveat of these 
findings is that a large quantity of PVL (12 µg) is needed to cause accumulation 
of IL-8 and MCP-1 in rabbit lungs (52). Diep et al. (52) proposed that increased 
severity of S. aureus infection is attributed in part to degranulation of PMNs 
following exposure to PVL in vivo, which in turn causes damage to the lungs and 
prolongs the proinflammatory response. It is notable that Diep et al. (52) utilized 
a very large inoculum of PVL-positive S. aureus in the pneumonia model and a 
high concentration of purified PVL to elicit a proinflammatory response in the 
rabbit lung.  
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  Hla clearly contributes to the severity of staphylococcal disease in animal 
models, while the contribution of PVL is limited or undetectable. Perhaps this 
difference can be partially explained by the ability of Hla to target a much wider 
range of cell types as compared to PVL. As demonstrated by Suttorp et al. (53), 
exposure of pulmonary endothelial monolayers to Hla increases permeability of 
the monolayer by stimulating cell retraction, i.e. formation of paracellular gaps. 
These results suggest that Hla disrupts the air-blood barrier in pulmonary tissue 
not by cytolysis but by altering cell morphology and/or function. Subsequent 
studies by McElroy et al. (54) and Bubeck Wardenburg et al. (50) demonstrated 
that expression of Hla in an animal pneumonia model caused disruption of the 
air-blood barrier via destruction of lung tissue.  
  In comparison to Hla, PVL may have a more subtle role in the progression 
of staphylococcal pneumonia and/or may contribute in rare syndromes (i.e., 
necrotizing pneumonia). It is also possible that particular host factors increase 
leukocyte susceptibility to PVL or cause an aberrant proinflammatory response 
following exposure to PVL. Further studies will be necessary to test these 
hypotheses.   
  There is redundancy in the cytolytic and proinflammatory function of S. 
aureus cytolytic toxins; however, studies in vivo demonstrate that not all are 
created equal. Hla is a key virulence factor in staphylococcal pneumonia and 
SSTIs as exemplified by the ability of anti-Hla antibodies to protect S. aureus-
infected mice from severe or lethal disease (50,55). By comparison, anti-PVL 
antibodies confer no protection against S. aureus infection in animal pneumonia 
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models (50). Antibodies that cross-react with PVL are present in the general 
human population, with or without a medical history of S. aureus infection (56-
59). Notably, anti-PVL antibodies fail to protect individuals from recurrent 
infections caused by PVL-positive CA-MRSA strains USA300 and USA400 
(60,61). 
 
4.1.4 Concluding thoughts. 
  The ability of sublytic concentrations of PVL to augment the 
proinflammatory response (Chapter 3 and 37-40) could be detrimental to 
surrounding host tissues. Increased release of proinflammatory agents, such as 
IL-8 and IL-1β, from leukocytes would lead to increased inflammation and the 
potential for unintended host tissue damage. A countering argument to this 
notion is that the PVL-mediated release of inflammatory molecules enhances the 
innate immune response, and therefore, expression of PVL in vivo could be 
advantageous to the host for clearance of infection. This idea is further supported 
by Yoong et al., who demonstrated reduced clearance of USA300 and USA400 
infection after administration of anti-PVL antibodies (62). In light of these and 
other previous findings that indicate anti-PVL antibodies are not protective 
against subsequent S. aureus infection (60,61), it is particularly concerning that a 
monovalent or bivalent recombinant LukS-PV toxoid vaccine human trial is 
underway (http://www.clinicaltrials.gov/ct2/show/NCT01011335?term=panton 
valentine+leukocidin&rank=2).  Host production of anti-PVL antibodies after 
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vaccination with this LukS-PV toxoid may actually worsen the outcome of S. 
aureus infection rather than providing some benefit to the host. 
  Based on previous studies and work presented in this dissertation, we 
propose that PVL functions primarily as an immune modulatory agent rather than 
a cytolytic toxin. How would a PVL-enhanced proinflammatory response be 
advantageous to S. aureus as a commensal organism or pathogen? It is possible 
that such a proinflammatory response limits dissemination and disease severity, 
thereby promoting a long-term commensal interaction with the human host. PVL-
mediated alterations in the proinflammatory response are perhaps advantageous 
for S. aureus, particularly in certain host niches or time points during infection. 
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